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 Abstract 
Oral drug absorption, and therefore efficacy, can be affected by food-drug 
interactions. Consequently, during drug development, clinical studies are carried out 
in adults to determine the effect of food on the pharmacokinetic profile of the drug. 
However, such studies are rarely carried out in children, despite sometimes having 
different food-drug effects to adults. Furthermore, as medicines are often 
administered to children with food, it is important to understand which foods can and 
cannot be used in the administration of different drugs. The aim was to see which 
food components have the greatest effect on the absorption of two drugs commonly 
used in paediatrics, in order to discover which foods can be used to administer these 
drugs to children. This was achieved by undertaking solubility and dissolution 
experiments on propylthiouracil and penicillin V in media representing the fasted and 
fed states, and ranges of pH, fat, calcium, protein, and fibre contents. All 
concentrations of protein used caused a significant reduction in propylthiouracil 
solubility and dissolution. Furthermore, propylthiouracil dissolution was significantly 
reduced by fed state solutions, and media at more neutral pH, and high fat or 
calcium contents. Penicillin dissolution was strongly affected by media of low pH and 
high protein concentrations. In conclusion, propylthiouracil is best administered to 
children with more acidic foods, such as apple sauce or fruit juice, while more neutral 
foods high in fat, calcium and protein, for example milk and yoghurt, should be 
avoided. Conversely, penicillin V should be delivered with neutral foods, but not 
acidic foods. 
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1.0 Introduction 
1.1 Food-drug interactions 
It is widely known that food-drug interactions can affect the oral absorption, and 
therefore the efficacy and/or toxicity, of a drug [1-3]. As a result, during drug 
development, fed effect clinical studies must be undertaken to assess if, compared 
to the fasted state, food causes a clinically significant difference in the peak plasma 
concentration (Cmax) of the drug, the time to Cmax (Tmax), and the area under the 
absorption curve (AUC), where plasma concentration of the drug is plotted against 
time. Food can affect the amount of drug absorbed, which has important clinical 
significance. If food reduces the absorption of the drug, then the patient does not 
receive the desired dosage, thus reducing the drug’s efficacy. However, it is also 
possible for food to increase the absorption of a drug, resulting in the patient 
receiving more than the desired dosage. This can cause the patient to experience 
adverse effects of the drug, which is not desirable. Alternatively, food can affect the 
rate of drug absorption, which generally has less clinical significance, but can have 
greater impact when using modified-release formulations [1-4]. For example, a slow-
release drug is designed to take longer to break down in the gut, but still provide the 
desired dosage. However, if food slows transit time through the gut, the slow-release 
drug is releasing its contents into the gut for a longer period of time, resulting in 
increased drug absorption, which may lead to increased adverse effects, as 
previously stated. These fed effect studies provide important information when 
determining the most appropriate dosage and timing of new drugs. Due to the 
importance of food-drug interactions, there is detailed guidance on conducting fed 
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effect studies in adult populations, which are strictly adhered to when carrying out 
such studies [5, 6]. 
1.2 Effects of the different food components 
Not only can food interact with the drug itself to affect its solubility and absorption in 
a physico-chemical food-drug interaction, but food can also affect gastrointestinal 
physiology. However, the  composition of food can have different results, because 
the various components of food exert different effects on the gastrointestinal system 
[7]. The effects of assorted food components (pH, fat, calcium, protein and fibre) are 
illustrated in Table 1 below. 
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Table 1 – A summary of the physiological effect of various food components on the 
gastrointestinal system, and of the physico-chemical effects of various food 
components on the absorption of drugs. Gastric emptying is the emptying of the 
stomach contents into the small intestine, where absorption occurs. Chelation is the 
binding of drugs to metal cations, such as calcium ions (Ca2+). Drugs can also bind to 
protein and fibre molecules within the gastrointestinal tract. Both chelation and 
binding reduces drug absorption. (Adapted from [7]) 
1.2.1 Standard meal 
The regulatory guidance mentioned in Section 1.1 states that a standard breakfast 
should be used in fed effect clinical studies. This meal is usually in the form of a fried 
breakfast, because this meal is high-fat, with a calorific content of 800-1000kcal, with 
fat constituting 50-65% of this energy, carbohydrates 25-30%, and protein 15-20%. 
This will have the largest effect on gastrointestinal physiology, thus providing a ‘worst 
case scenario’ in terms of the effect food can have on the oral absorption of the drug 
in question [5, 6]. 
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1.3 Food-drug effects in paediatrics 
Despite there being strict regulations on fed effect clinical studies in adults, very little 
has been done to investigate food-drug interactions in paediatrics. This is because 
data from adults is usually extrapolated down to paediatrics, thus assuming that 
children will respond to the drug in the same way as adults [8, 9]. However, as stated 
below, there are fundamental differences between adults and paediatrics that result 
in different food-drug interactions in the two populations, as described in Section 
1.3.1 below. This means that children may not be receiving the maximum therapeutic 
benefit from a drug, or might even be receiving increased toxicity from a drug, due to 
altered extents and/or rates of drug absorption. In fact, fed effect studies actually 
carried out in paediatric populations have revealed several drugs with different 
responses to food compared to the data from adults. Some of these are described 
below. This shows that we cannot assume that food will affect a drug in the same 
way in adults and children, thus highlighting the importance of carrying out fed effect 
clinical studies in paediatric populations.  
However, due to the absence of regulations on fed effects clinical studies in 
paediatric populations, there is no standard meal for the various age ranges. This 
means that, unlike adult studies, where the standard meal allows studies to be 
compared, there is a huge variety in the meal given in food effect studies in 
paediatric populations. This means that it is hard to compare the data from different 
studies, which creates confusion. 
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1.3.1 Drugs with different food-drug effects in paediatrics compared to 
adults 
As previously stated in Section 1.3, several drugs have been found to have different 
food-drug effects when tested in fed effect clinical studies in paediatric populations 
compared to in adult populations.  
Three of these drugs are amoxicillin, ampicillin and penicillin V 
(phenoxymethylpenicillin), which are all used to treat bacterial infections [10-12]. 
When tested in adults with a 500mg dose administered after the standard breakfast, 
there was no effect on amoxicillin absorption [13], but there was reduced Cmax and 
AUC of ampicillin [13]. However, when an oral suspension of amoxicillin or ampicillin 
at a dose of 15 or 25mg/kg was tested in paediatrics (4-45 months, mean age of 27 
months) with 4oz milk or formula, the opposite effect was seen, i.e. there was 
reduced Cmax of amoxicillin at 15mg/kg dosage (although not at 25mg/kg dosage) 
[14], whereas there was no effect on ampicillin absorption [14]. It is recommended to 
take penicillin V in the fasted state in adults due to slight effects in its absorption [15]. 
Two different studies in paediatric populations show that both the Cmax and AUC of 
penicillin V were reduced when administered with breakfast in older children (6 
months – 5 years) [16] and with milk in infants [17], confirming that food, particularly 
milk, reduces penicillin V absorption. 
Another drug where food has no effect on its absorption in adults is propylthiouracil 
[18], which is used to treat hyperthyroidism [19]. However, when administered with 
food in paediatric populations, Tmax was increased, while Cmax was reduced and 
AUC was variable [20]. 
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Conversely, desmopressin is an example of a drug that has a known food-drug effect 
in adults, but not in children. Desmopressin is an analogue of vasopressin, which 
acts on the kidneys to reduce urine production, and is used in the treatment of 
conditions such as diabetes insipidus (not diabetes mellitus) and bedwetting in older 
children [21]. In adults, food reduces both Cmax and AUC of desmopressin [22]. 
When given with the standard meal in older children (mean age 12.7 years), the 
absorption of desmopressin was not affected [23]. 
1.4 Differences between adults and paediatrics 
1.4.1 Physiology 
Table 2 – Summary of the pH values of the stomach and intestine, and of the transit 
time through the stomach and intestine, in a variety of age ranges. Due to the 
presence of amniotic fluid in the gastrointestinal tract, neonates are born with a 
stomach pH of 6-8, which lowers a few hours after birth, and rises again to pH 6-7 due 
to reduced acid secretion in the stomach. As this secretion increases with age, 
stomach pH falls gradually to pH 1-2 after approximately two years. There is little data 
on the intestinal pH of neonates and infants, but there is little difference between 
intestinal pH in children, adolescents and adults. Transit time through the stomach (or 
gastric emptying time – emptying of the stomach’s contents into the small intestine) 
becomes more variable with age, due to the effects of a more varied diet on the 
gastrointestinal system . Transit time through the small intestine is longer in neonates 
and infants, as it gradually falls with age. (Adapted from [4]) 
7 
 
Table 2 illustrates some of the differences in the gastrointestinal physiology of adults 
and children. These have certain implications for drug absorption, as detailed below. 
Neonates have a variable gastric (stomach) pH, which may have an impact on oral 
drug absorption, particularly on the absorption of weak acids and weak bases (Table 
1). The reduced gastric secretion in neonates results in fewer active gastric 
enzymes, which also impacts on drug absorption [4]. However, this increased gastric 
pH can mean greater absorption of acid labile drugs, such as penicillin [4], as the 
drug is more stable at higher pH.  
As the main site of drug absorption is the small intestine, the rate of emptying the 
stomach contents into the small intestine (known as gastric emptying) is often the 
rate limiting step in drug absorption. Up until six months of age, infants have slower 
gastric emptying, resulting in slower drug absorption and subsequently slower Tmax 
[4]. 
Irregular intestinal motility in neonates and infants results in variable transit times of 
food through the small and large intestines, ranging from 8-96 hours, compared to 2-
48 hours in adults [4]. Conversely, children tend to have a faster gut transit time, 
which may result in incomplete absorption of modified-release drugs because the 
drug passes through without releasing the whole dose [4]. These differences in 
transit time results in different rates and extents of drug absorption, which has a 
knock-on effect on bioavailability and efficacy of the drug. 
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1.4.2 Diet 
Table 3 – Recommended calorific input and proportion of carbohydrate to fat to 
protein in the diet for different age ranges and genders. Calorific input increases with 
age, with males requiring more calories than females. The ratio of carbohydrate to fat 
to protein is similar for most age ranges, but infants have different nutritional needs, 
as fat contributes a greater percentage to the diet, while less protein is required. 
(Adapted from [24]) 
As shown in Table 3, adults and children have different nutritional needs. Fat is the 
main energy source for infants less than six months old, but as the infant matures, 
this slowly changes so that carbohydrate becomes the main energy source [24]. This 
has implications for the physiology of the gut and for oral drug absorption, as a high 
fat content slows gastric emptying, but also enhances the solubility of less water-
soluble drugs, as shown in Table 1. 
Table 3 also illustrates that the standard meal for food-effect clinical studies in adults 
(see Section 1.2.1 above) is the worst case scenario of a meal, considering the daily 
recommended calorific intake and composition for adults. The standard meal is 
nearly half the daily recommended calories, and has almost double the daily 
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recommended fat content. As previously stated in Table 1, this means that the 
digestive system will be greatly altered, having the greatest effect on drug 
absorption. 
1.4.3 Compliance 
The absence of guidelines on fed effect clinical studies in paediatric populations like 
those for adults has resulted in most paediatric pharmacokinetic studies being 
undertaken in the fasted state. However, this is not representative of administering 
drugs to paediatric populations. Children are often unable and/or unwilling to swallow 
tablets with water alone. Consequently, drugs are often crushed and mixed with soft 
foods, such as apple sauce or yoghurt, or drinks, such as fruit juice or milk, in order 
to make the drug both more palatable and easier to consume, thus facilitating the 
administration of the drug [25, 26]. This is not just done in the home – medical 
professionals will also mix drugs with food when administering to paediatrics [25], 
and the British National Formulary for Children (BNF-C) recommend certain drugs to 
be mixed with food or drink in order to facilitate its administration [26]. 
1.5 Aims 
As previously stated, food is known to affect the oral absorption of many drugs, and 
therefore it is often recommended to take them on an empty stomach. However, little 
is known about how food affects drug absorption in paediatric populations, despite 
this being a very important issue, as children are rarely administered drugs without 
food or drink.  
The aim of this project is to identify which component(s) of food (pH, fat, calcium, 
protein or fibre) have the strongest influences on the solubility and dissolution of 
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propylthiouracil and penicillin V – two drugs commonly used in paediatrics that have 
been found to have different food-drug effects in paediatrics compared to adult 
populations (see Section 1.3.1). 
Subsequently, this information could be used to best advise both parents and 
medical professionals which foods can be used, and which are best avoided, when 
administering these drugs to paediatric populations. 
2.0 Materials and Methods 
2.1 Preparation of solubility and dissolution media 
2.1.1 Fasted State Simulated Intestinal Fluid (FaSSIF) and Fed State 
Simulated Intestinal Fluid (FeSSIF) 
To make 1L blank FaSSIF or blank FeSSIF; 0.348g sodium hydroxide pellets (Sigma 
Aldrich), 4.470g sodium dihydrogen phosphate dehydrate (Fischer Scientific) and 
6.186g sodium chloride (Fischer  Scientific); or 4.04g sodium hydroxide pellets, 
144ml 1M acetic acid solution (Sigma Aldrich) and 11.874g sodium chloride, 
respectively, were added to approximately 900ml deionised water and stirred until 
dissolved using a magnetic stirrer. The pH was adjusted to pH 6.8 or pH 5.0, 
respectively, using 0.2M NaOH (Thermo Scientific) or 0.2M HCl (Thermo Scientific) 
as required, then transferred to a 1L volumetric flask and made up to volume with 
deionised water. 
To make 1L FaSSIF or FeSSIF; 1.65g sodium taurocholate (Sigma Aldrich) and 
0.59g lecithin (Lipoid EPC); or 8.25g sodium taurocholate and 2.95g lecithin, 
respectively, were added to 200ml blank FaSSIF or blank FeSSIF, respectively, and 
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stirred overnight on a magnetic stirrer to form a clear micellar solution. On day 2, 
these solutions were transferred to separate 1L volumetric flasks and made up to 
volume with blank FaSSIF or blank FeSSIF, respectively.  
Solutions were made fresh immediately before the first use, then stored at room 
temperature until stocks were used up before making up from fresh again. 
2.1.2 pH buffer solutions 
To make 1L solutions at pH 2.6, pH 4.6, pH 6.6 or pH 7.4; 891ml, 532.5ml, 272.5ml, 
or 91.5ml 0.1M citric acid (Fischer Scientific), respectively, were mixed together with 
109ml, 467.5ml, 727.5ml, or 908.5ml 0.2M di-sodium hydrogen phosphate dehydrate 
(BDH Laboratory Supplies), respectively.  
The solutions above represent a highly acidic diet, a less acidic diet, intestinal pH 
and blood pH, respectively. 
Solutions were made fresh immediately before the first use, then stored at 4oC until 
stocks were used before making up from fresh again. 
2.1.3 Fat 
To make 1L solutions at 6%, 22% or 34% fat; 27.08g Light Coffee-Mate (Nestle), 
150g First Infant Milk (Cow and Gate), or 27.08g Original Coffee-Mate (Nestle), 
respectively, were added (as per manufacturer’s instructions) to 1L volumetric flasks 
and made up to volume with blank FaSSIF. The solutions were mixed via manual 
inversion. 
Solutions were made fresh immediately before the first use, then stored at 4oC for up 
to one week before making up from fresh again. 
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2.1.4 Calcium 
To make 1L solutions at 0.2mg/ml, 0.5mg/ml, 1mg/ml or 2mg/ml calcium; 200mg, 
500mg, 1000mg, or 2000mg calcium chloride (Sigma Aldrich), respectively, were 
added to 1L volumetric flasks and made up to volume with blank FaSSIF and stirred 
until dissolved using a magnetic stirrer. 
Solutions were made fresh immediately before the first use, then stored at 4oC until 
stocks were used before making up from fresh again. 
2.1.5 Protein 
To make 1L solutions at 2%, 4%, 6% or 8% protein; 20g, 40g, 60g, or 80g casein 
(Fischer Scientific) respectively was added to 1L volumetric flasks and made up to 
volume with blank FaSSIF. The solutions were mixed via manual inversion. 
Solutions were made fresh immediately before the first use, then stored at 4oC until 
stocks were used before making up from fresh again. 
2.1.6 Fibre 
To make 200ml solutions at half, normal and double the manufacturer’s 
recommended concentration for 6-12 year olds; half a teaspoon (2.5ml), 1 teaspoon 
(5ml), or 2 teaspoons (10ml) Fybogel Orange (Reckitt Benckiser), respectively, was 
added (as per manufacturer’s instructions) to 200ml blank FaSSIF. The solutions 
were mixed via manual inversion. 
Solutions were made fresh immediately before the first use, then stored at 4oC until 
stocks were used before making up from fresh again. 
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2.2 HPLC  Methodology 
The HPLC (high performance liquid chromatography) machine used consisted of 
Dionex Ultimate 3000 series pump, Auto Samplers and Diode Array Detectors 
(Thermo Scientific), and the software used to analyse the samples was Dionex 
Chromeleon Software Version 7.1 SR1 (Thermo Scientific). Ten µl of each sample 
was put through an ODS Hypersil C18 column, dimensions: 150mmx4.6mm; particle 
size: 5µm (Thermo Scientific), using the appropriate mobile phase below. 
For propylthiouracil, mobile phase (50% methanol (Sigma Aldrich); 50% water; v/v) 
was used with the above column at 1ml/min flow rate for a run time of 5 minutes. UV 
detection was performed at 276nm. Retention time was approximately 2.2 minutes.  
For penicillin V, mobile phase (47% acetonitrile (Fischer Chemical); 3% methanol; 
50% 0.01M monobasic potassium phosphate buffer (Sigma Aldrich); v/v/v) was used 
with the same column at 1.5ml/min flow rate for a run time of 3 minutes. UV 
detection was performed at 255nm. Retention time was approximately 0.9 minutes. 
2.3 Calibration 
First, stock solutions of 0.1mg/ml for propylthiouracil powder (Cambridge 
Biosciences) or 5mg/ml for penicillin V potassium powder (LKT Laboratories) were 
prepared. Then, a calibration series of 5 different concentrations from this stock 
solution were prepared (final concentrations of 0.06, 0.07, 0.08, 0.09 and 0.1mg/ml 
for propylthiouracil; 1, 1.5, 5, 2.5 and 3mg/ml for penicillin V). HPLC analysis was 
used to measure the drug concentration in 10µl of each dilution, using the 
appropriate method in Section 2.2 above. The area under the curve for each 
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penicillin V sample was recorded, whereas the peak height for each propylthiouracil 
sample was recorded. 
2.3.1 Data Analysis 
In Microsoft Excel, the area under the curve (penicillin V) or peak height 
(propylthiouracil) was plotted against concentration of each dilution. A trend line was 
fitted to the data using least squares linear regression analysis using the equation    
y = mx + c, where y is area under curve or peak height, x is drug concentration, and 
m and c are the gradient and intercept of the calibration curve, respectively. The 
correlation coefficient (R2) of the calibration curve was also calculated. 
2.4 Solubility Measurement 
Excess drug powder (1mg propylthiouracil; 5mg penicillin V) was added to a 1.5ml 
Eppendorf tube, and then 1ml media was added. The tubes were vortexed and then 
shaken at 37oC for 4 hours within a water bath. Three replicates were prepared for 
each condition. The tube was centrifuged for 5 minutes at 12,000xg to separate the 
supernatant, and then the supernatant was removed and used for HPLC analysis, 
using the appropriate method in Section 2.2 above. 
2.4.1 Data Analysis 
In Microsoft Excel, the appropriate equation of the trend line from the calibration was 
used to calculate the drug concentration in each sample from its area under the 
curve (penicillin V) or peak height (propylthiouracil). The mean and standard 
deviation of the triplicates was calculated and plotted. 
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2.5.2 Statistics 
In Microsoft Excel, Student’s t-tests were only carried out on any samples that had 
error bars outside of the range of that of blank FaSSIF – the control, reference 
medium. 
2.5 Dissolution 
180ml of media was added to a 200ml dissolution vessel, and then one tablet (50mg 
propylthiouracil (Focus Pharmaceuticals); 250mg penicillin V (Bristol Laboratories) – 
both supplied by UHB Pharmacy) was added to the vessel. The rotation speed of the 
paddle was at 75rpm (or 100rpm for the calcium, protein, and fibre solutions). The 
vessels were incubated at 37oC for 4 hours, with a 1ml sample being taken at fixed 
time points (0, 15, 30, 45, 60, 120, 180 and 240 minutes) and replaced with 1ml 
fresh solution to maintain the net volume at 180ml. The samples were then analysed 
using the appropriate HPLC method in Section 2.2 above. 
2.5.1 Data Analysis 
In Microsoft Excel, the appropriate equation of the trend line from the calibration was 
used to calculate the drug concentration in each sample from its area under the 
curve (penicillin V) or peak height (propylthiouracil). The concentration of each 
sample was then used to calculate the amount of drug released at that time point. 
This was used to calculate the amount of drug released as a percentage of the total 
mass of drug contained in the tablet. The mean and standard deviation of each 
triplicate was calculated and plotted to show the dissolution of the drug over time. 
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2.5.2 Statistics 
To assess whether there was any statistically significant difference between the 
dissolution in a particular medium compared to the control, reference medium (blank 
FaSSIF), the f1 and f2 factors [27, 28] were calculated using Microsoft Excel, where f1 
is the difference factor between two dissolution curves, and f2 is the similarity factor. 
In order for two dissolution curves to be significantly different, the f1 value must be 
above 15 and the f2 value must be below 50. 
3.0 Results 
3.1 Summary of Results 
In this study, the effect of a range of different food components (pH, fat, calcium, 
protein and fibre) on the solubility and dissolution profiles of the drugs 
propylthiouracil and penicillin V was investigated. The different media investigated 
were: blank FaSSIF, FaSSIF, blank FeSSIF, FeSSIF, and solutions at pH 2.6, pH 
4.6, pH 6.6, pH 7.4, 6% fat, 22% fat, 34% fat, 0.2mg/ml Ca2+, 0.5mg/ml Ca2+, 1mg/ml 
Ca2+, 2mg/ml Ca2+, 2% protein, 4% protein, 6% protein, 8% protein, manufacturer’s 
recommended concentration of fibre for 6-12 year olds, half of this recommended 
concentration of fibre, and double this recommended concentration of fibre. The 
results from the different media were compared to that of blank FaSSIF, which acted 
as a control, reference medium to assess the solubility and dissolution of the two 
drugs in a fasted state, in the absence of bile salts and fats. Table 4 below 
summarises the results, showing whether any medium significantly changed the 
solubility and/or dissolution of either drug compared to that of blank FaSSIF, or not. 
The results are discussed in detail below. 
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Table 4 – A summary of the solubility and dissolution of propylthiouracil and 
penicillin V in a range of different media. The media used are: blank FaSSIF, blank 
FeSSIF, FaSSIF, FeSSIF, pH 2.6, pH 4.6, pH 6.6, pH 7.4, 6% fat, 22% fat, 34% fat, 
0.2mg/ml Ca2+, 0.5mg/ml Ca2+, 1mg/ml Ca2+, 2mg/ml Ca2+, 2% protein, 4% protein, 6% 
protein, 8% protein, half concentration of fibre, normal concentration of fibre, double 
concentration of fibre. The solubility measurements and dissolution profiles for all 
other media were compared to the reference media, blank FaSSIF. ↓ indicates a 
significant reduction in drug solubility/dissolution compared to that in blank FaSSIF; 
↔ indicates no significant change in drug solubility/dissolution compared to that in 
blank FaSSIF. 
Table 4 above summaries the solubility and dissolution of propylthiouracil and 
penicillin V in media containing different levels of various food components (as 
detailed in the figure legend) compared to the results from the control media, blank 
FaSSIF. Most media had no significant effect, especially on penicillin V, where none 
of the results were significantly different from the control. However, all of the media 
containing different levels of protein caused a significant reduction in the solubility 
and dissolution of propylthiouracil compared to blank FaSSIF. Other media that 
caused a significant reduction in the rate of dissolution of propylthiouracil were: blank 
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FeSSIF, FeSSIF, pH 6.6, 22% fat, 34% fat, and 2mg/ml Ca2+. All other media had no 
significant effect on propylthiouracil dissolution. Unfortunately, some of the data were 
uninterpretable due to signal interference (as detailed in the figure legend). The 
results are discussed in more detail below. 
3.2 Solubility of Propylthiouracil 
 
Figure 1 – Summary of the solubility of 1mg propylthiouracil powder in 1ml of media 
(as indicated in the legend to the right) after 4h incubation at 37oC. Data are the mean 
concentration (n = 5 for blank FaSSIF; n = 3 for all other media), error bars are 
standard deviation. 
Figure 1 above shows the solubility of 1mg propylthiouracil powder in 1ml of various 
media (see figure legend to the right of the graph). The solubility in the control 
media, blank FaSSIF, (far left) was 0.54 ± 0.18mg/ml. The only media to cause a 
significant reduction (p < 0.05) in propylthiouracil solubility were the media with 
varying concentrations of protein (0.02 ± 0.03 for 2% protein; 0.18 ± 0.05 for 4%; 
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0.20 ± 0.08 for 6%; 0.14 ± 0.02 for 8%). Media at pH 6.6, 34% fat, and all four 
calcium concentrations also appear to reduce propylthiouracil solubility, although this 
is insignificant. Blank FeSSIF appears to decrease propylthiouracil solubility even 
further, but this is still not significant. Conversely, FaSSIF and FeSSIF and media at 
6% fat and 22% fat appear to increase the solubility of propylthiouracil, although this 
is insignificant, particularly as there was a lot of variation between the triplicates in 
the media at 6% and 22% fat. Media at pH 2.6 and 4.6 appear to increase 
propylthiouracil solubility even further, but this is still insignificant. 
3.3 Dissolution of Propylthiouracil 
 
Figure 2 – Dissolution profiles of one 50mg propylthiouracil tablet in 180ml of various 
media (as indicated in the legend to the right) over 4 hours at 37.4oC. Data are the 
mean mass of drug released at each time point, expressed as a percentage of the total 
mass of drug in the tablet (n = 3). 
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Figure 3 – Dissolution profiles of one 50mg propylthiouracil tablet in 180ml of media 
with different pH values (A), fat contents (B), calcium concentrations (C) or protein 
concentrations (D) (as indicated in the legends to the right of each of the graphs) over 
4 hours at 37.4oC. Data are the mean mass of drug released at each time point, 
expressed as a percentage of the total mass of drug in the tablet (n = 3). 
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Figures 2 and 3 above show the dissolution profiles of propylthiouracil in a variety of 
media (see figure legends to the right of each of the graphs). Each profile was 
compared to that of the control media, blank FaSSIF (Fig. 2; blue diamonds). The 
f1/f2 test (see Section 2.5.2) was performed to see if there was a significant 
difference in the dissolution profile in each medium compared to that of blank 
FaSSIF. In blank FeSSIF and FeSSIF, the rate of propylthiouracil dissolution was 
significantly reduced, whereas it was not affected by FaSSIF (Fig. 2). The rate of 
dissolution of propylthiouracil was also significantly reduced in media at pH 6.6 (Fig. 
3A), 22% fat, 34% fat (Fig. 3B), 2mg/ml Ca2+ (Fig. 3C), 2% protein, 4% protein, 6% 
protein, and 8% protein (Fig. 3D). Dissolution was not significantly affected by any of 
the other media.  
 
 
 
 
 
 
 
 
 
22 
 
3.4 Solubility of Penicillin V 
 
Figure 4 - Summary of the solubility of 5mg penicillin V powder in 1ml of media (as 
indicated in the legend to the right) after 4h incubation at 37oC. Data are the mean 
concentration (n = 5 for blank FaSSIF; n = 3 for all other media), error bars are 
standard deviation. 
Figure 4 above shows the solubility of 5mg penicillin V powder in 1ml of various 
media (see figure legend to the right of the graph). The solubility in the control 
media, blank FaSSIF, was 4.34 ± 1.28mg/ml. None of the media had a statistically 
significant effect, despite FeSSIF and media at 22% fat appearing to give a 
significant increase in penicillin V solubility. FaSSIF and media at pH 6.6, all four 
calcium concentrations, 2% protein, and 4% protein, all appear to increase the 
solubility of penicillin V, although this is insignificant. Blank FeSSIF and media at pH 
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4.6, pH 7.4, 6% fat, 34% fat, 6% protein, and 8% protein, all appear to reduce the 
solubility of penicillin V; however, this is not significant. 
3.5 Dissolution of Penicillin V 
 
Figure 5 - Dissolution profiles of one 250mg penicillin V tablet in 180ml of various 
media (as indicated in the legend to the right) over 4 hours at 37.4oC. Data are the 
mean mass of drug released at each time point, expressed as a percentage of the total 
mass of drug in the tablet (n = 3). 
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Figure 6 – Dissolution profiles of one 250mg penicillin V tablet in 180ml of media with 
different pH values (A), fat contents (B), calcium concentrations (C) or protein 
concentrations (D) (as indicated in the legends to the right of each of the graphs) over 
4 hours at 37.4oC. Data are the mean mass of drug released at each time point, 
expressed as a percentage of the total mass of drug in the tablet (n = 3). 
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Figures 5 and 6 above show the dissolution profiles of penicillin V in a variety of 
media (see figure legends to the right of each of the graphs). Each profile was 
compared to that of the control media, blank FaSSIF (Fig. 5; blue diamonds). The 
f1/f2 test (see Section 2.5.2) was performed to see if there was a significant 
difference in the dissolution profile in each medium compared to that of blank 
FaSSIF. However, the rate of dissolution of penicillin V was not significantly affected 
by any of the media, as at least 90% penicillin V was released from the tablet within 
the first 15 minutes in all of the media. 
4.0 Discussion 
4.1 Effect of fasted and fed states 
Compared to blank FaSSIF (the control, reference fasted state media, which does 
not contain bile salts or fats), both FaSSIF and FeSSIF caused a slight increase in 
the solubility of propylthiouracil, whereas blank FeSSIF resulted in a decrease its 
solubility (Fig. 1), although none of these changes were significant. Conversely, both 
blank FeSSIF and FeSSIF significantly reduced the dissolution profile of 
propylthiouracil, but FaSSIF had no effect (Fig. 2). While this data is mixed, it would 
seem that the solubility and dissolution of propylthiouracil is reduced in the fed state, 
which has been shown previously [20].  
While there was no significant difference in the rate of dissolution of penicillin V in 
blank FeSSIF, FaSSIF or FeSSIF compared to blank FaSSIF (Fig. 5), its solubility 
appeared to be affected, albeit insignificantly (Fig. 4). FaSSIF resulted in a slight 
increase in solubility, whereas blank FeSSIF resulted in a slight decrease in 
solubility. FeSSIF seemed to cause a massive increase in penicillin V solubility to 
around 15mg/ml. However, this cannot be believed as, while FeSSIF does contain 
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various fats and surfactants which can increase drug solubility, this is a three-fold 
increase in drug concentration from the initial 5mg of penicillin V powder added to 
1ml media (see Section 2.4), which seems unlikely to be achieved by the contents of 
FeSSIF alone. It is unclear what caused this very large difference – it is too big to be 
human error, so it might have been an error in the HPLC machine, for example, it 
may have had some residual drug in it, as this sample was run after running the fibre 
media through it (this media was difficult to analyse using the current HPLC method 
– for more details, see Section 4.6). Consequently, this experiment needs repeating 
in order to determine the real solubility of penicillin V in FeSSIF, as time constraints 
prevented this from occurring. Similar to propylthiouracil, despite the data being 
mixed, it appears that the solubility and dissolution of penicillin V is also reduced in 
the fed state, which has been shown before [16, 20]. 
Consequently, it would be best to advise that both propylthiouracil and penicillin V be 
given on an empty stomach and without food, in order to maintain optimal drug 
efficacy. This is what is currently advised, however, as previously discussed, this is 
rarely possible in paediatrics. In the sections below are details of the effects of each 
of the specific food components on the solubility and dissolution of both drugs to see 
which components have the greatest effect, in order to best advise both parents and 
medical professionals which foods and drinks to avoid when giving either drug to 
children. 
4.2 Effect of pH 
The data from propylthiouracil solubility in pH 7.4 media, and penicillin V solubility in 
pH 2.6 media, were uninterpretable due to interference with the HPLC signal (Table 
4). It would seem that this was due to instability and degradation of the drug products 
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in these media [29], which meant that it was difficult to identify which peak 
represented the intact drug product, as desired, and which were a result of 
degradation. Consequently, the dissolution experiment was not carried out for these 
drugs in their respective media.  
The rate of dissolution of propylthiouracil was significantly reduced in pH 6.6 media, 
but was unaffected by media at lower pH (Fig. 3A). Furthermore, the solubility 
appeared to be reduced in pH 6.6 media, but increased in media at lower pH, 
although this is insignificant (Fig. 1). This, combined with the instability and 
degradation of the drug product in pH 7.4 media (Table 4), suggests that 
propylthiouracil is less stable at more neutral pH values. It would be interesting to 
see if propylthiouracil stability is affected at higher pH, as this would show if it is the 
fact that the drug is more stable at lower pH, or just unstable at neutral pH. Either 
way, this is less likely to be problematic in practice, as few foods are within the 
alkaline pH range, and the physiological pH of the digestive system tends to be lower 
than neutral. However, this is more likely to have an effect in infants, whose diets 
tend to be comprised of milk, which has a pH of around 6.7 [30, 31]. Consequently, it 
would be best to advise parents to avoid giving their child propylthiouracil around the 
time of feeding them milk. 
The solubility and dissolution of penicillin V was not significantly affected by any of 
the pH media (Figs. 4 and 6A), indicating that pH has no effect on penicillin V. 
However, as previously stated, the data from its solubility in media at pH 2.6 was 
unreadable, most likely due to degradation of the drug product [29]. Furthermore, its 
solubility in media at pH 4.6 was 3.90 ± 0.15mg/ml, compared to 4.34 ± 1.28mg/ml in 
blank FaSSIF. This shows that the solubility of penicillin V is reduced at lower pH, 
and at low pH, the drug product itself becomes broken down by the acidic 
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environment [29]. Consequently, it would be best to advise parents to avoid giving 
their child penicillin V with acidic foods and drinks because it would reduce the drug’s 
efficacy. This is particularly important to stress, as parents often give the crushed 
tablet mixed with apple sauce, or dissolved in fruit juices, which have a pH of around 
3.4 [31], and thus is likely to cause degradation of the drug product. Conversely, Fig. 
4 shows that penicillin V solubility was also reduced in media at pH 7.4, implying that 
the drug’s solubility may also be affected by more neutral pH. However, as the error 
bars are quite large, this effect is questionable and requires more repeats to 
investigate this further, as time constraints prevented this from occurring. 
4.3 Effect of fat 
Propylthiouracil solubility was not significantly affected by fat (Fig. 1); however there 
was a large amount of variation between the triplicates, indicating that the 
experiments may need to be repeated to confirm this, as time constraints prevented 
this from occurring. In contrast, its dissolution profile was significantly different in 
higher fat contents, suggesting that fat reduces the rate of dissolution of 
propylthiouracil. This indicates that parents should be advised against giving this 
drug with high-fat foods and drinks, as it is likely to reduce its efficacy. However, 
children’s diets are quite high in fat because, unlike adults – whose energy is derived 
mostly from carbohydrate, children (infants in particular) obtain most of their energy 
from the calories in fat [24] (see Table 3). Moreover, milk is a large component of the 
diet, especially in babies and infants, and yoghurt is another common foodstuff that 
drugs are mixed with before being given to a child [25, 26], and these foods can be 
quite high in fat [30, 32]. Consequently, fat can have quite a large impact on the 
efficacy of drugs in children. However, as nutritional contents are now readily 
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available on product packaging, it is possible to purchase the foodstuffs with the 
lowest fat content – this is likely to be good advice to parents, as they will have the 
option to still use these commonly used foodstuffs when administering drugs to their 
children, whilst improving the efficacy of the drug. 
While Fig. 6B shows that the dissolution of penicillin V was not significantly affected 
by fat, Fig. 4 shows a mixed effect of fat on penicillin V solubility, although this is not 
significant. Both 6% and 34% fat media resulted in a decrease in solubility, 
suggesting that fat reduces the solubility of penicillin V, which has been seen 
previously [16, 17]. However, the decrease is larger in the 6% media, which is 
unexpected. Opposing this, 22% fat media resulted in an increase in solubility to 
nearly 6mg/ml, which is greater than the 5mg of penicillin V powder added to 1ml of 
media (see Section 2.4), suggesting that this result is unreliable and that it needs to 
be repeated, as time constraints prevented this from occurring. However, this media 
was made from infant formula milk, rather than normal milk powder like the other two 
media, meaning that more powder was needed to make the 22% media, 
subsequently making this media much thicker, which may have interfered with the 
HPLC readings. Consequently, it would be worth repeating this experiment with 
media from more comparable sources to make the results more reliable, as time and 
resource constraints prevented this from occurring. From this data, no conclusions 
can be drawn on the effect of fat on penicillin V, but it is advisable to warn parents to 
try and avoid giving penicillin V with high-fat foods and drinks, by either administering 
with an alternative foodstuff, or purchasing lower-fat variants, in order to improve the 
efficacy of the drug. 
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4.4 Effect of calcium 
Fig. 1 shows that calcium reduced propylthiouracil solubility, but in a concentration-
independent manner. However, this is not a significant effect. Additionally, Fig. 3C 
shows that only media at 2mg/ml calcium caused a significant reduction in the rate of 
propylthiouracil dissolution. As calcium only altered the dissolution profile at high 
concentrations, and only had a small, statistically insignificant effect on solubility, it 
seems that calcium content of the foods or drinks given with propylthiouracil is not a 
great concern to the efficacy of the drug, as long as the calcium levels are not too 
high. However, children’s diets are quite high in calcium, as milk is a large 
component of the diet, especially in babies and infants. Furthermore, yoghurt is 
another common foodstuff that drugs are mixed with before being given to a child. As 
dairy products are high in calcium [30, 32], for example, 100g milk and 100g fruit-
flavour yoghurts designed for children both contain approximately 120µg calcium [30, 
32], it is worth making parents aware that giving propylthiouracil with milk or yoghurt 
can reduce the drug’s efficacy. 
Fig. 6C shows that the dissolution profile of penicillin V was unaffected by the 
presence of calcium. Conversely, Fig. 4 seems to show that calcium causes an 
increase in penicillin V solubility, again in a concentration-independent manner, 
although this is not significant. However, we must be cautious with this data, despite 
it having very tight error bars, because the concentrations of penicillin V in all four 
media are slightly over 5mg/ml (the initial concentration of penicillin V powder when 
added to the media – see Section 2.4). Consequently, these experiments should be 
repeated to see if this is an effect of calcium, or inaccurate weighing, as time 
constraints prevented this from occurring. These data suggest that the efficacy of 
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penicillin V is unaffected by calcium, so foods and drinks high in calcium need not be 
avoiding when making penicillin V more palatable for children, although this requires 
further investigation. 
However, in the calcium media, there was an increasing amount of visible solid 
particles suspended in solution as calcium concentration increased. As a result, 
these particles might have been taken up into the HPLC machine, thus affecting the 
reading of the drug concentration. Consequently, the data in Fig. 3C showing that 
the rate of dissolution of propylthiouracil was significantly reduced in media at 
2mg/ml Ca2+ may not be true. However, as the dissolution of penicillin V in media at 
2mg/ml Ca2+ was not affected, nor was the dissolution of either drug affected in 
media at lower calcium concentrations, we can be more confident that this data is 
true. Still, it may be best to repeat the experiment, using filters on the syringes when 
sampling in order to remove these particles, as time constraints prevented this from 
occurring. This would allow the HPLC machine to more accurately measure the drug 
concentration of each sample, without the risk of signal interference from calcium 
chloride particles. 
4.5 Effect of protein 
As shown in Figs. 1 and 3D, both the solubility and dissolution of propylthiouracil 
were significantly reduced in all of the protein media (p < 0.05). However, there does 
not seem to be a definite concentration-dependent effect, as the solubility in the four 
different protein media is variable, and there is no significant difference between the 
dissolution profiles in the three protein media investigated. This suggests that protein 
affects propylthiouracil independently of its concentration. However, it may be worth 
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investigating this further with more repeats, as a slight trend can be seen, but time 
constraints preventing this from happening. 
Conversely, neither the solubility nor the dissolution of penicillin V was significantly 
affected by the protein media, suggesting that protein has no significant effect on 
penicillin V. However, Fig. 4 does show decreased penicillin V solubility with 
increased protein concentration. Further repeats may reveal that this is a significant 
effect, as time constraints prevented this from occurring, but it may be that protein 
only has a significant effect on penicillin V solubility at higher concentrations than 
those investigated here, and thus are less likely to be physiologically relevant. 
Despite this, it is still worth investigating the effect of higher protein concentrations 
on the solubility and dissolution of penicillin V, but time constraints prevented this 
from happening. 
As milk and yoghurts are also high in protein [30, 32], it may be best to advise that 
parents avoid giving either drug with these foodstuffs or around the time of 
consuming them, in order to prevent the protein affecting the absorption of the drug. 
However, as previously stated, it is now possible to purchase the foodstuffs with the 
lowest protein content due to nutritional information on food packaging, meaning that 
parents still have the option to still use these commonly used foodstuffs when 
administering drugs to their children whilst improving the efficacy of the drug. 
Unfortunately, no results were obtained from the dissolution of either drug in the 8% 
protein media. This was because of strong signal interference, resulting in 
unreadable data. Like the calcium media, the protein media had some visible solid 
particles suspended in solution, which increased with increased protein 
concentration. It may have been that these particles entered the HPLC machine, 
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causing the measurement of drug content to be reduced, rather than a true effect of 
the protein concentration on drug dissolution. Similarly, the use of filters on the 
syringes during sampling would allow this to be investigated further, but time 
constraints prevented this from happening. 
As a consequence of these particles being present, the results from Figs. 1 and 3D 
showing that propylthiouracil solubility and dissolution were significantly reduced in 
the protein media may just be an artefact, due to signal interference from the large 
casein particles suspended in solution in all four of the different protein media. Again, 
use of syringes would help to show if this was a true effect. However, as the 
solubility and dissolution of penicillin V was not significantly changed in the protein 
media, we can be more confident that the observed effect of protein on 
propylthiouracil solubility and dissolution is true. 
4.6 Effect of fibre 
As stated in Table 4, there were no results obtained from any of the experiments 
carried out in the fibre media because the data was unreadable. This could be due to 
one of several reasons. It may be that the visible particles suspended in the Fybogel 
media were taken up into the HPLC machine and thus affected the results, in a 
similar way to the results from the protein media and higher calcium concentrations 
might have been affected. Likewise, the way to investigate whether this is the case is 
to use filters on the syringe when sampling, as time constraints prevented this from 
happening. Alternatively, it may be that the fibre media were too viscous to be 
suitable for the current dissolution protocol. Despite increasing the rotation speed to 
100rpm, it may be that any dissolved drug was unable to be evenly dispersed 
throughout the media, resulting in unreadable data. Furthermore, it may be that, in 
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the current HPLC set up, the HPLC machine was unable to take up the same 
amount of fibre media each time. Consequently, the HPLC methodology would have 
to be optimised to consistently take up 10µl of a more viscous solution. However, 
time constraints prevented this from happening. In spite of this, the problem may lie 
within the media used itself, for example, preventing adequate dispersion of the 
dissolved drug product. If this is the case, an alternative method for investigating the 
effect of fibre would need to be found, as time and resource constraints preventing 
this from being investigated. 
4.7 Improvements to penicillin V dissolution experiments 
From these experiments, it would seem that the rate of dissolution of penicillin V is 
unaffected by any food components (Figs. 5 and 6). However, it may be that food 
components do affect the dissolution profile, but at a more subtle level than the 
above methods detailed in Section 2.5 can detect. Consequently, it may be worth 
modifying the protocol to take samples every 5 minutes for 30 minutes, for example, 
to see if there are any significant differences during this period, as time constraints 
prevented this from being carried out. These differences would have less of an 
impact on drug efficacy than those detected within the normal sampling range, as 
they are more subtle, but are still worth examining. 
4.8 Further work 
In this project, the in vitro effect of these food components on the solubility and 
dissolution of propylthiouracil and penicillin V was investigated. It would be beneficial 
to then investigate if the in vivo effect is similar, by conducting fed effect clinical 
studies in children, looking at a range of meal compositions, differing in pH, and the 
content of fat, calcium, protein and fibre, in order to support these results. 
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It would also be useful to investigate whether any effect can be observed in various 
commonly used food stuffs, such as yoghurt, milk, and apple sauce, both in vitro and 
in vivo, in order to confirm these results.  
4.9 Conclusions 
These data show that the absorption of propylthiouracil would be most affected by 
foodstuffs with high fat, calcium and protein contents, and higher pH. Consequently, 
it would be best to advise parents against giving this drug to children with milk or 
yoghurt, for example. However, propylthiouracil may be administered with foods 
such as apple sauce or fruit juice, as this will have less of an effect on its oral 
absorption. 
Less conclusive data is available from these experiments on which food components 
significantly affect penicillin V absorption. However, it would be best to advise 
parents against giving this drug to children with apple sauce or fruit juices, as low pH 
seems to degrade the drug. Alternatively, penicillin V may be administered with 
foods like milk or yoghurt, as calcium and protein seem to have less of an effect on 
the oral absorption of penicillin V. However, as fat may have a negative effect on the 
absorption of penicillin V, it may be best to recommend administering with low fat 
milk or yoghurt in order to improve drug efficacy. 
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Abstract: 
Medullary thyroid cancer (MTC) is a rare, aggressive tumour type. Most hereditary 
and half of sporadic MTC cases are caused by activating mutations in the Ret proto-
oncogene. However, hereditary MTC has recently been found to be associated with 
inactivating mutations in oestrogen receptor β (ERβ). Oestrogen acting through ERβ 
initiates anti-proliferative signalling pathways in order to restrain cell growth. When 
functional ERβ is lost through mutation, this regulation may be lost, potentially 
resulting in tumourigenesis. The aims of this project were to see if significant ERβ 
knockdown could be achieved in SW1736 and MCF7 cell lines, and whether this 
knockdown has any effect the expression of Ret, cyclin D1 and IGF-1R (other 
oestrogen-responsive genes involved in cell proliferation). ERβ knockdown was 
carried out by transfecting specific siRNAs. RNA and protein expression were 
determined by quantitative-PCR and Western blotting, respectively. Significant ERβ 
knockdown was achieved at the protein level in SW1736 cells, and at the RNA level 
in MCF7 cells. In ERβ knocked-down MCF7 cells, cyclin D1 RNA levels trended 
towards decreased expression, whereas IGF-1R RNA levels trended towards 
increased expression in the presence of oestrogen. From these data, it is unlikely 
that MTC arises due to pro-proliferative changes in Ret or cyclin D1 expression, as 
RNA levels of these genes were statistically unchanged when levels of functional 
ERβ were significantly reduced, or when oestrogen was present. However, these 
data do suggest that MTC might arise due to increases in IGF-1R expression in 
cases where expression of functional ERβ is reduced. 
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1.0 Introduction 
1.1 Medullary thyroid cancer 
Medullary thyroid cancer (MTC) is a rare tumour of the parafollicular C cells in the 
thyroid gland [1-5]. Thyroid cancer makes up approximately 1% of all cancers 
worldwide [6], and MTC is responsible for approximately 5% of all thyroid cancers [2, 
3, 5, 7, 8]. Generally, MTC is a more aggressive form of thyroid cancer [7], with 
metastases to lungs, liver and bone occurring early [2], and prognosis becoming 
worse with increased age and/or more advanced stage at diagnosis [7]. 
MTC is sporadic in 75% of cases. In the other 25% of cases, MTC is hereditary, in 
the form of either multiple endocrine neoplasia (MEN) 2A, 2B, or familial (FMTC) [2-
5, 7, 8]. MEN2A and 2B are also often associated with other neoplasms, such as 
phaeochromocytoma (tumours of the adrenal medulla) [3]. While MEN2A usually 
presents in the third decade of life if it is not detected through genetic screening (see 
Section 1.7), MEN2B tends to be more aggressive and usually presents very early – 
often in the first year of life [3]. Conversely, FMTC is rarely associated with any other 
neoplasm, and is less aggressive than MEN, typically presenting in the fourth 
decade of life [3]. The gene that is mutated in hereditary MTC and half of sporadic 
cases of MTC is Ret [7, 9-12]. 
1.2 Ret signalling 
1.2.1 Structure 
The rearranged during transfection (Ret) proto-oncogene was found in 1985 to be 
located on chromosome 10q11.2 [11-13]. The gene encodes a receptor tyrosine 
kinase, which is 170kDa in size and found on the cell surface [9, 11, 13]. Alternative 
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splicing of the gene results in three main isoforms: Ret9, Ret49, and Ret51, also 
referred to as the short-, medium- and long-domains, respectively [9, 12]. The 
protein domains of Ret are shown below in Fig. 1. 
 
Figure 1 – Protein domains of the rearranged during transfection (Ret) receptor 
tyrosine kinase proto-oncogene. The N-terminal (N) extracellular domain is 
responsible for ligand binding, and consists of four repeats of cadherin-like motifs 
(blue) and a cysteine-rich domain (red). The transmembrane domain (TD) is a short, 
hydrophobic region (purple). The C-terminal (C) intracellular region consists of a 
tyrosine kinase domain, with several tyrosine residues (green). This is the functional 
domain, which becomes activated upon ligand binding and is responsible for 
activating downstream signalling cascades. (Adapted from [7, 9, 11]) 
As shown in Fig. 1, the intracellular tyrosine kinase domain located towards the C 
terminus of the Ret protein is activated when the ligand binds to the extracellular 
domain (found towards the N terminus of the protein), and is responsible for 
activating the various downstream signalling cascades [7, 9, 11], as shown in Fig. 2 
below. 
1.2.2 Signalling 
 
Figure 2 – Activation pathway of the rearranged during transfection (Ret) receptor 
tyrosine kinase proto-oncogene. Glial cell derived neurotrophic factor (GDNF; green 
diamond) binds to a member of the GDNF receptor α (GDNFα) family (purple 
rectangle). Ret (blue rectangle) homodimerisation results in autophosphorylation of 
the tyrosine kinase domains (orange circles labelled ‘P’). The three main signalling 
pathways downstream of activated Ret are: Ras/Raf/mitogen-activated protein kinase 
(MAPK)/extracellular signal-related kinase (ERK); c-Jun N-terminal kinases (JNK); 
phosphatidylinositol 3’-kinase (PI3K)-Akt, which all promote cell survival, growth, 
differentiation and migration. (Adapted from [4, 7, 9, 11, 12]) 
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The endogenous ligand of Ret is glial cell derived neurotrophic factor (GDNF), which 
is a member of the neuronal growth factor family. Ret is activated by GDNF binding 
to a glycosylphosphatidylinositol (GPI)-anchored co-receptor from the GDNF 
receptor α (GDNFα) family, as shown in Fig. 2. This results in the homodimerisation 
of Ret, which facilitates autophosphorylation of the tyrosine kinase domains, thus 
activating Ret [7, 9, 11, 12]. Once Ret is activated, it can then stimulate various 
downstream signalling cascades. The three main cascades promoted by Ret are the 
Ras/Raf/mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase 
(ERK) pathway, the c-Jun N-terminal kinases (JNK) pathway, and the 
phosphatidylinositol 3’-kinase (PI3K)-Akt pathway [4, 7, 12]. Activation of these 
pathways results in cell growth, survival, migration and differentiation [7, 9]. 
1.3 The role of Ret mutations in cancer 
As activated Ret is responsible for promoting cell growth, survival and migration, 
when Ret is mutated to become constitutively active, there is uncontrolled cell 
proliferation, resulting in the formation of tumours. 
As previously stated in Section 1.1, Ret is often mutated in MTC. Activating Ret 
mutations in the germline are responsible for hereditary forms of MTC [3-5, 7, 8]. In 
MEN2A, Ret tends to be mutated within the cysteine-rich domain [3, 4], whereas the 
Ret mutation most commonly seen in MEN2B is M918T, which is associated with an 
increased risk of metastases, thus resulting in a decreased survival rate and worse 
prognosis [3, 4, 7]. Furthermore, somatic Ret activating mutations cause 
approximately half of all sporadic cases of MTC [3-5, 7, 8]. This shows that Ret is an 
important factor in the initiation and development of MTC. 
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1.4 Other factors that may be involved in medullary thyroid cancer 
Several different genes have also been found to be altered in MTC, and 
consequently may be useful targets for MTC therapies. 
Various growth factors and their receptors are known to be involved in MTC. It has 
been found that vascular endothelial growth factor receptor (VEGFR) and epidermal 
growth factor receptor (EGFR) are often overexpressed in MTC [3-5, 14]. Insulin-like 
growth factor type-1 receptor (IGF-1R) can also be overexpressed in MTC [12]. 
Activation of these receptors and their subsequent downstream signalling pathways 
can result in the initiation and progression of MTC, due to enhanced tumour growth 
(through increased cell proliferation and survival) and invasion [7, 12]. 
Another factor recently found to be altered in MTC is oestrogen receptor β (ERβ). A 
number of patients with hereditary MTC but lacking a Ret mutation have been 
discovered to have a mutation in the ERβ gene [unpublished observation]. 
Furthermore, normal parafollicular C cells express ER, and transformed cells 
maintain the ability to synthesise ER [1], suggesting that oestrogen signalling is 
important in malignant parafollicular C cells. 
1.5 Oestrogen receptor signalling 
1.5.1 Structure 
Oestrogen (17β-oestradiol; E2) is a steroid hormone known to regulate a vast range 
of cellular processes, including cell survival, proliferation and differentiation, across 
the whole body – not just in the male and female reproductive systems [15]. 
Oestrogen signalling is most commonly mediated by the binding of oestrogen to the 
oestrogen receptor (ER) – a nuclear receptor (see Section 1.5.2). There are two 
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isoforms of the ER: ERα and ERβ. While the ERα gene is located on chromosome 
6q25.1 and encodes a 66kDa protein [16], and the ERβ gene is located on 
chromosome 14q23.2 and encodes a 56kDa protein [17], they both have a similar 
modular protein structure [18], as shown in Fig. 3 below. 
 
Figure 3 – Protein domains of the oestrogen receptor (ER). At the N-terminus (N), 
there is the ligand-independent activation function-1 (AF-1). The C domain (red) 
contains the DNA binding domain (DBD). The D domain contains the nuclear 
localisation signal (NLS). Towards the C-terminus (C), there is the ligand binding 
domain (LBD) and the ligand-dependent activation function-2 (AF-2). (Adapted from 
[15, 18, 19]) 
Fig. 3 shows the modular structure of ERα and ERβ. The N-terminal A/B domain 
contains the ligand-independent activation function-1 (AF-1). The C domain contains 
the DNA binding domain (DBD), which allows the ER to bind to oestrogen response 
elements (EREs) in DNA. The D domain is also known as the hinge region, as it can 
rotate to give different conformations of ER. This domain also contains the nuclear 
localisation signal (NLS). The E domain contains both the ligand-dependent 
activation function-2 (AF-2) and the ligand binding domain (LBD), which is where 
oestrogen can bind to the ER. Furthermore, this domain can interact with other ERs, 
resulting in homo- and heterodimerisation, and with heat-shock proteins and other 
chaperone proteins. However, the functions of the C-terminal F domain are still 
unclear [15, 18, 19]. The ERα and ERβ proteins have conserved DBD and LBD 
regions, allowing both receptors to bind to oestrogen and EREs, but they have 
different N-terminal structures, resulting in different biological responses to 
oestrogen (see Section 1.5.2) [6, 20]. However, both receptors are activated in the 
same way, as shown below. 
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1.5.2 Signalling  
 
Figure 4 – The classical (genomic) pathway of oestrogen receptor (ER) signalling. 
When oestrogen (green diamond) is absent, ER (blue) is bound within a multi-protein 
inhibitory complex (red circles). Activated ER binds to oestrogen receptor elements 
(ERE) in the DNA, along with various co-activators and transcription factors (purple 
triangles), and RNA polymerase II (orange) to regulate transcription of target genes. 
(Adapted from [6, 15, 18, 20-22]) 
The main mechanism of ER signalling is the classical, or genomic, pathway, as 
shown in Fig. 4. In the absence of oestrogen, the ER is sequestered by chaperone 
proteins in the nucleus, such as heat-shock proteins, maintaining ER in an inactive 
form within the inhibitory complex [15, 21, 22]. When oestrogen binds to the ER, 
there is a conformational change within the ER, which facilitates dissociation of the 
chaperone proteins and dimerisation of ER. It has been shown that 
heterodimerisation can occur, as well as homodimerisation, resulting in slightly 
different biological responses. This dimerisation allows the ER to bind to the DNA at 
specific EREs, which have a conserved DNA sequence of AGGTCA [6, 15, 20, 21]. 
The ER also recruits various co-factors to the transcription start site, such as co-
activators, co-repressors, transcription factors, and RNA polymerase II, in order to 
regulate transcription of the target genes [6, 15, 18]. These co-factors are 
responsible for either modulating the interaction between the ER and the 
transcription machinery, or remodelling the chromatin structure. Various co-
activators possess histone acetyltransferase, which acetylates N-terminal lysine 
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residues of histones, thus neutralising the positive charge of the lysine residues, 
which decreases the affinity of histones for the negatively-charged DNA. This opens 
up the DNA structure, facilitating binding of transcription machinery to gene promoter 
regions [15]. Conversely, various co-repressors possess histone deacetylase, which 
reverses histone acetylation, resulting in a more compact DNA structure, thus 
preventing the binding of the transcription machinery [15]. 
However, this is not the only mechanism of ER signalling. A membrane-bound ER, 
the G protein coupled receptor GP30, has recently been found [21, 23]. Signalling 
through this novel receptor results in the activation of various signalling cascades, 
such as the MAPK and ERK pathways, or the release of intracellular calcium [6, 15, 
18, 21, 22]. This is a much more rapid form of oestrogen signalling, as there is a 
much shorter lag time between oestrogen binding and signalling output, because 
there is no transcription or translation required [15]. 
Another method of ER signalling is known as transcription factor cross-talk, in which 
activated ERs interact with various transcription factors, such as activating protein-1 
(AP-1) and stimulating protein 1 (SP1) [18]. Activated ERs have been found to 
activate or repress genes that are responsive to these transcription factors in 
different ways, depending on the cell type, receptor and promoter [15]. 
There is also a ligand-independent pathway of ER signalling. Activation of growth 
factor receptors, such as EGFR and IGF-1R, results in the stimulation of various 
signalling cascades, which can result in the activation of ER or its co-receptors, even 
in the absence of ligand [18, 19, 21]. Furthermore, the phosphorylation status of ER, 
and therefore its activity, can be regulated depending on the balance of kinases and 
phosphatases that act on the ER [24]. 
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It has been observed that ERα and ERβ have different expression profiles, as well 
as different biological functions, as illustrated by the distinct phenotypes of ERα 
knockout animals compared to ERβ knockout animals, suggesting that they play 
different roles in oestrogen signalling in health and disease (for more details, see 
Section 1.6) [6, 18, 20, 22, 23]. Not only do the two isoforms regulate the activity of 
each other due to the competition for binding to EREs [6, 20], but ERβ has been 
found to inhibit ERα activity through decreasing the sensitivity of ERα to oestrogen, 
and through promoting ERα degradation [6, 18, 20]. This shows that ERβ is also 
critical for regulating oestrogen signalling itself, indicating that this is an important 
regulatory protein. 
1.6 The role of oestrogen receptors in cancer 
Oestrogen has been found to play a role in several different types of cancer, namely 
breast, ovarian, endometrial, colonic and prostate cancers [18], and has recently 
been thought to be involved in MTC (see Section 1.4). The main way in which 
oestrogen signalling is altered in cancer is through an increased ERα:ERβ ratio (i.e. 
increased expression of ERα and/or decreased expression of ERβ) [2]. It has been 
shown that oestrogen signalling through ERα promotes tumour initiation and 
progression by increasing cell growth, while signalling through ERβ opposes tumour 
development by preventing cell growth [2, 21]. ERα and ERβ also have different 
influences on the expression of cyclin D1 [18], a key protein in the regulation of the 
cell cycle, as it facilitates progression from the G1 phase to the S phase [6, 21, 25-
27]. Oestrogen signalling through ERα increases the expression of cyclin D1, thus 
promoting cell proliferation, whereas oestrogen signalling through ERβ decreases 
cyclin D1 expression, thus inhibiting cell proliferation [2, 18]. Additionally, when 
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thyroid cancer cell lines were treated with the ERα agonist propyl-pyrazole-triol 
(PPT), there was increased cell proliferation and expression of the anti-apoptotic 
protein B cell lymphoma-2 (Bcl-2), but when the cell lines were treated with the ERβ 
agonist diarylpropionitrile (DPN), cell proliferation was inhibited and Bcl-2 expression 
was reduced [6, 21]. Furthermore, tumours that still express ERβ are associated with 
a better prognosis because the tumour tends to be much less aggressive [2]. This 
shows that ERβ has a protective, anti-proliferative effect, which is often lost in 
cancers, resulting in unregulated cell proliferation, and thus tumour progression. 
1.7 Treatment of medullary thyroid cancer 
MTC does not respond to conventional cancer therapies, such as chemotherapy or 
radiation [2, 4, 5]. Therefore, the main form of treatment for MTC is total 
thyroidectomy [2, 4, 5], although response to this has been found to be improved by 
local lymph node dissection [4, 5]. Due to the severity of the disease, it is 
recommended that genetic screening of relatives of MTC patients is carried out, and 
that total thyroidectomy is undertaken in all those with activating Ret mutations as a 
prophylactic treatment, due to the aggressive nature of MTC [3]. 
However, there is now a drug treatment for metastatic MTC. These treatments 
involve the use of multiple tyrosine kinase inhibitors to target the signalling cascades 
responsible for promoting cell proliferation, survival and migration (see Section 1.4) 
[3-5, 7, 14]. The first United States Food and Drug Administration (US FDA) 
approved drug for the treatment of MTC was vandetanib, in April 2011 [4, 5, 7]. 
Vandetanib inhibits Ret, VEGFR and EGFR [3-5, 7, 14], and in clinical trials 
increased progression-free survival in patients with metastatic MTC from 9.3 to 30.5 
months [14]. However, vandetanib is not without its problems. Common side effects 
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include diarrhoea, nausea, headaches, rashes, and hypertension, but it was also 
found to significantly prolong the QT interval on electrocardiograms, thus increasing 
the risk of developing the fatal heart condition Torsades de pointes [3, 4, 7]. An 
alternative drug for treating metastatic MTC is cabozantinib, which inhibits Ret, 
VEGFR and hepatocyte growth factor receptor (HGFR) [7, 14], and in clinical trials 
increased progression-free survival in patients with severe metastatic MTC from 4.0 
to 11.2 months [14]. However, the toxicology profile of cabozantinib is still high, with 
90% of patients experiencing at least one side effect – the most common being 
gastrointestinal disturbances [7]. 
Consequently, there is a demand to develop novel treatments that are more 
successful at treating MTC, with fewer adverse effects. In order to achieve this, we 
need greater understanding of the signalling processes behind MTC so that we can 
find new targets for therapeutics. By increasing our knowledge of the role ERβ plays 
in MTC, we may be able to target this signalling pathway and develop a new 
treatment for MTC. 
1.8 Aims and hypotheses 
It has been observed that there is an increased ERα:ERβ ratio in MTC [21]. 
Furthermore, mutations in the ERβ gene have been found in a number of patients 
with hereditary MTC who lack a mutation in the Ret gene [unpublished observation], 
supporting the idea that mutated ERβ results in the initiation and/or progression of 
cancer. This thesis investigates the hypothesis that ERβ mutations results in Ret 
hyperactivity, through disruption of ERβ-mediated Ret inhibition, and that this is a 
key pathway involved in MTC development these cases. 
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In order to do this, the first aim was to achieve successful (i.e. more than 70%) 
knockdown of ERβ by transfecting anti-ESR2 siRNA into two different cell lines: 
SW1736 (a human thyroid carcinoma cell line) and MCF7 (a human breast 
carcinoma cell line). Both of these cell lines have been confirmed previously by the 
McCabe lab to be oestrogen-responsive (so contain both ERα and ERβ) and 
express Ret, as shown by quantitative-PCR (q-PCR).  
The next aim was to see if successful knockdown of ERβ had any significant effect 
on the level of RNA expression of Ret in SW1736 and MCF7 cells, using q-PCR. 
The final aim was to discern the effect of treating ERβ-knockdown MCF7 cells with 
17β-oestradiol (E2) on the amount of RNA expression of ERβ, Ret and the 
oestrogen-responsive genes cyclin D1 and insulin-like growth factor type-1 receptor 
(IGF-1R), via q-PCR. 
2.0 Materials and Methods 
2.1 Cell culture 
The cell lines SW1736 (human thyroid carcinoma) and MCF7 (human breast 
carcinoma) were obtained from The American Type Culture Collection. Both cell 
lines were maintained at 37oC and 5% CO2 in complete RPMI 1640 media [+] L-
glutamine from Gibco (containing 10% foetal bovine serum (FBS; Gibco) and 1% 
penicillin/streptomycin (Pen/Strep; Gibco)) in 75cm3 Corning flasks. When the cell 
lines reached 90% confluency, usually twice a week, they were sub-cultured at a 1:6 
or 1:10 dilution, respectively. The medium was aspirated from the cells, washed with 
PBS (5x phosphate buffered saline tablets (Sigma) in 500ml dH2O), trypisinised 
(0.025% Trypsin/EDTA, Invitrogen) for approximately 1 minute at 37oC, and then 
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transferred to new 75cm3 flasks containing fresh complete RPMI medium at 
approximately 37oC in the cell densities described. 
For transfection, both cell lines were seeded at 60,000 cells/well in a 12-well plate for 
subsequent RNA extraction, and 150,000 cells/well in a 6-well plate for subsequent 
protein extraction, and maintained at 37oC and 5% CO2. 
2.2 Transfection 
24 hours after seeding, cells were transfected with 50nM or 100nM either AllStars 
negative control siRNA (Qiagen) or anti-ESR2 Silencer® Select Pre-designed siRNA 
(s4826, s4827 or s4828; Ambion) using HiPerFect transfection reagent (Qiagen) 
according to manufacturer’s instructions. SW1736 cells were transfected with 50nM 
or 100nM negative siRNA or one of the three anti-ESR2 siRNAs. MCF7 cells were 
transfected with 100nM negative siRNA or a combination of the s4826 and s4827 
anti-ESR2 siRNAs. Each experimental condition for RNA transfection was repeated 
four times, while each experimental condition for protein transfection was repeated 
twice. 
Transfection mixes were prepared as follows:  
For RNA extraction of SW1736 cells, 12µl HiPerFect and either 6µl 10µM siRNA + 
82µl Opti-MEM reduced serum media (Gibco); or 12µl 10µM siRNA + 76µl Opti-
MEM, were mixed to give 100µl of transfection mix at 50nM or 100nM siRNA, 
respectively, for one well.  
For RNA extraction of MCF7 cells, 12µl HiPerFect and either 12µl 10µM negative 
siRNA + 76µl Opti-MEM; or 6µl of each 10µM anti-ESR2 siRNA + 76µl Opti-MEM, 
were mixed to give 100µl of transfection mix at 100nM siRNA, for one well. 
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For protein extraction of SW1736 cells, 24µl HiPerFect and either 12µl 10µM siRNA 
+ 64µl Opti-MEM; or 24µl 10µM siRNA + 52µl Opti-MEM, were mixed to give 100µl 
of transfection mix at 50nM or 100nM siRNA, respectively, for one well. 
For protein extraction of MCF7 cells, 24µl HiPerFect and either 24µl 10µM negative 
siRNA + 52µl Opti-MEM; or 12µl of each 10µM anti-ESR2 siRNA + 52µl Opti-MEM, 
were mixed to give 100µl of transfection mix at 100nM siRNA, for one well. 
Transfection mixes were vortexed, incubated for 10 minutes at room temperature, 
and vortexed again before 100µl was added drop-wise to each respective well. Each 
condition was replicated four times for RNA extraction, and twice for protein 
extraction. Cells were incubated at 37oC and 5% CO2. 
2.3 Oestrogen treatment 
17β-oestradiol (Sigma Aldrich) was resuspended in ethanol to 10mM, and stored at  
-20oC for up to a month. MCF7 cells were sub-cultured at a 1 in 10 dilution into 
75cm3 Corning flasks containing complete charcoal-stripped, clear RPMI 1640 media 
(Gibco) containing 10% FBS and 1% Pen/Strep (as in Section 2.2). Cells were 
incubated for 48 hours at 37oC and 5% CO2 before seeding into 12-well and 6-well 
plates in charcoal-stripped media at the densities specified in Section 2.1 above. 24 
hours after seeding, cells were transfected using the transfection mixes above. 24 
hours after transfection, the 10mM 17β-oestradiol was diluted to 5µM with water. 
Then, 5µM 17β-oestradiol was added to each well, to give a final concentration of 
10nM oestrogen. After 6 hours of oestrogen treatment, cells in the 12-well plates 
were harvested; the cells in the 6-well plates were harvested after 24 hours of 
oestrogen treatment. 
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2.4 RNA extraction using RNeasy MicroKit 
24 hours after transfection, medium was aspirated from the wells; cells were washed 
with PBS, and 250µl TRI-reagent (Sigma) was added to each well. After 5 minutes 
incubation at room temperature, this was transferred into a clean 1.5ml Eppendorf 
tube and stored at -80oC overnight. 
Once samples were thawed the next day, 50µl chloroform (Sigma) was added to 
each tube, and then the tubes were inverted 30 times before being left to stand at 
room temperature for 15 minutes. Samples were centrifuged at 13,200rpm for 20 
minutes at 4oC, and 100µl of the clean, top, clear layer was transferred to a clean 
1.5ml Eppendorf. Then, 125µl 100% ethanol (Sigma) was added to each tube and 
samples were vortexed before being transferred to a separate column from the 
RNeasy® Micro Kit (Qiagen), as per manufacturer’s instructions. These instructions 
were followed to complete the RNA extraction into 14µl RNase-free water (Qiagen). 
The RNA concentration of each sample was measured using the NanoDrop. 
2.5 Reverse transcription polymerase chain reaction (RT-PCR) 
Using the RNA concentrations of each sample as determined above, each sample 
was diluted using RNase-free water (Qiagen) to give 200ng or 400ng RNA in 5µl for 
the SW1736 and MCF7 cell lines, respectively. Samples were incubated at 70oC for 
10 minutes, span down and put on ice. A master mix from the reagents in the 
Reverse Transcription System (Promega) was prepared as per manufacturer’s 
instructions, and 5µl of this was added to each sample. Two negative control 
samples were also run during each experiment. Samples were incubated at room 
temperature for 15 minutes before being incubated at 42oC for 1 hour, then 95oC for 
5 minutes, and then 4oC for 5 minutes. Samples were centrifuged at 13,200rpm for 
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30 seconds and 10µl of RNase-free water was added to each sample before being 
stored at -20oC. 
2.6 Quantitative polymerase chain reaction (q-PCR) 
PCR master mixes were prepared as follows: 7µl RNase-free water + 10µl 2x 
GoldStar Taqman PCR master mix (Eurogentec) + 1µl 20x Taqman gene expression 
assay (Applied Biosystems) – this is for one well. To assay for the desired genes 
ESR2, Ret, cyclin D1, IGF-1R and the control gene 18S, the following Taqman 
assays were used: Hs00230957_m1 ESR2, Hs01120030_m1 RET, 
Hs00765553_m1 CCND1, Hs00609566_m1 IGF1R, and QuantumRNATM classic 
18S internal standard respectively. The 18S Taqman assay uses a Vic reporter and 
a TAMRA quencher, while all the other Taqman assays use a FAM reporter and a 
TAMRA quencher. 
To each assigned well of a 96-well plate, 2µl and 18µl of the appropriate sample and 
master mix, respectively, was added. Each sample was run on the plate in duplicate. 
The plate was sealed thoroughly with a film lid, centrifuged at 2,000rpm for 30 
seconds, and ran on a Taqman PCR machine. 
2.6.1 Data Analysis 
In Microsoft Excel, delta CT values and fold changes were calculated from the CT 
values for each sample and gene assayed. The mean CT values and fold change for 
each experimental condition was plotted, with error bars representing standard 
deviation for delta CT values, and standard error of the mean for fold changes. 
Student’s t-test was performed using Microsoft Excel to test for significance             
(p < 0.05).  
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2.7 Protein extraction 
48 hours after transfection, medium was aspirated from the wells, cells were washed 
with PBS, and 150µl RIPA/PI/PhI solution was added to each well. This solution was 
made up of 1ml RIPA lysis buffer : 60µl protease inhibitor cocktail (Sigma) : 10µl 
HaltTM phosphatase inhibitor cocktail (Thermo Scientific). The RIPA lysis buffer was 
made in house and stored at 4oC, and was composed of 1.22g Trizma base (Sigma) 
+ 1.8g sodium chloride (Fischer Scientific) + 160ml dH2O + 2ml Igepal (Sigma) + 5ml 
10% sodium deoxycholate (Sigma) + 2ml 100mM EDTA (3.722g in 100ml; Sigma), 
adjusted to pH7.4 with HCl. Cells were incubated at -20oC for 15 minutes, and then 
each well was scraped and transferred to a 1.5ml Eppendorf tube. Samples were 
sonicated on medium for 30 seconds, before centrifuging at 12,000rpm for 10 
minutes at 4oC. The supernatant was transferred to a fresh 1.5ml Eppendorf tube 
and the protein concentration of each sample was measured using the BCA assay 
below, and the samples were stored at -20oC. 
2.8 BCA assay 
To each assigned well of a 96-well plate, 4µl of each sample and protein standards 
(0, 0.125, 0.5, 0.75, 1, 1.5, 2, 2.5 and 5mg/ml protein in RIPA buffer) was added in 
duplicate. Then, 80µl of BSA reagent (1ml reagent A : 20µl reagent B (Pierce® BCA 
assay, Thermo Scientific)) was added to each well. The plate was then incubated at 
37oC for 30 minutes. Protein concentration was then measured using a 
spectrophotometer and the programme Wallac Victor 3, using the ‘Absorbance 560’ 
protocol. 
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2.9 Western blotting 
Samples were incubated with protein sample buffer (0.107g DL-dithiothreitol (DTT; 
Sigma) + 1ml Laemmli sample buffer (Biorad)) for 5 minutes at 95oC before being 
loaded, along with molecular weight markers (Precision plus protein dual colour 
standards, Biorad), into a well of a 12% gel. The gel was made in house on Day 1 of 
the Western blot and comprised a 12% resolving gel, which was poured into the 
mould and left to set for 20 minutes, and a 5% stacking gel, which was poured into 
the mould on top of the set resolving gel. The comb was inserted into the stacking 
gel. The 12% resolving gel was composed of 2.4675ml dH2O + 1.875ml 1.5M Tris-
HCl at pH 8.8 (90.75g Trizma base + 500ml dH2O) + 3ml acrylamide (Protogel; 
National Diagnostics) + 75µl 10% sodium dodecyl sulphate (SDS; Sigma) + 75µl 
10% ammonium persulphate (APS; Sigma) + 7.5µl tetramethylethylenediamine 
(TEMED; Sigma). The 5% stacking gel was composed of 1.51ml dH2O + 0.625ml 
0.8M Tris-HCl at pH 6.8 (48.5g Trizma base + 500ml dH2O) + 312.5µl acrylamide + 
50µl 10% SDS + 50µl 10% APS + 5µl TEMED. Samples were ran with 1x running 
buffer (made in house and stored at room temperature – 10x running buffer, 
consisting of 30g Trizma base + 144g glycine (Sigma) + 10g SDS in 1L dH2O, was 
diluted to 1x with dH2O) at 140V for approximately 40 minutes, and then transferred 
to a PVDF nitrocellulose membrane (Amersham Hybond P PVDF membrane; GE 
Life Sciences) using transfer buffer (made in house and stored at room temperature 
– comprised of 6.06g Tris + 28.8g glycine + 400ml methanol + 1.6L dH2O) at 360mA 
for 75 minutes. Membranes were then blocked in TBST (made in house and stored 
at room temperature – comprised of 50ml 1M Tris at pH 7.6 (121.14g Trizma base in 
1L dH2O) + 20g 5mM sodium chloride + 0.625ml Tween-80 (Sigma) + 2449.4ml 
dH2O) + either 5% milk (Marvel) or 5% BSA (bovine serum albumin; Sigma) at room 
55 
 
temperature for at least 1 hour before being incubated at 4oC overnight in TBST + 
5% milk or BSA containing rabbit anti-ERβ primary antibody (ERβ (H-150): sc-8974; 
Santa Cruz) at a dilution of 1:200. Membranes were washed with TBST (three times 
five minute washes) before being incubated at room temperature for 1 hour in TBST 
+ 5% milk containing goat anti-rabbit secondary antibody (Dako) at a dilution of 
1:2,000. Membranes were washed with TBST (three times five minute washes) 
before being incubated in Pierce® ECL2 Western Blotting substrate (Thermo 
Scientific), as per manufacturer’s instructions, and then developed onto medical X-
ray film (Kodak) in the dark. 
As a control, membranes were re-probed for β-actin to ensure even protein loading. 
To do this, membranes were washed with TBST (three times five minute washes) 
before being blocked in TBST + 5% milk at room temperature for at least 1 hour 
before being incubated at 4oC overnight in TBST + 5% milk containing murine anti-
βactin primary antibody (Sigma) at a dilution of 1:10,000. Membranes were washed 
with TBST (three times five minute washes) before being incubated at room 
temperature for 1 hour in TBST + 5% milk containing rabbit anti-murine secondary 
antibody (Dako) at a dilution of 1:2,000. Membranes were washed with TBST (three 
times five minute washes) before being incubated and developed as above. 
2.9.1 Data Analysis 
The X-ray film was scanned and the file opened in Image J 1.45s software. Band 
density was analysed using pixel numbers in the allocated band area. In Microsoft 
Excel, the fold change for each experimental condition was calculated compared to 
the negative condition. Student’s t-test was performed using Microsoft Excel to test 
for significance (p < 0.05). 
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3.0 Results 
3.1 Data for SW1736 cells transfected with control or anti-ESR2 siRNA 
3.1.1 Quantitative-PCR 
3.1.1.1 ERβ 
SW1736 cells (a human thyroid carcinoma cell line) were transfected with either a 
negative control siRNA or one of three different anti-ESR2 siRNAs in order to see if 
significant knockdown of ERβ could be achieved at the RNA level in this cell line. 
Fig. 5 below shows the level of ERβ RNA expression in SW1736 cells transfected 
with either a negative control siRNA or one of three different siRNAs targeted against 
the ESR2 gene. Fig. 5A shows the mean delta CT values of ERβ RNA expression in 
each experimental group, with error bars representing standard deviation (SD). In 
the negative siRNA-transfected group, the mean delta CT value was 23.9 ± 0.2, 
which remained statistically unchanged when transfected with siRNA 1 (s4826), 
siRNA 2 (s4827), or siRNA 3 (s4828). Fig. 5B shows the mean fold change in ERβ 
RNA expression compared to the expression of the control gene 18S, with error bars 
representing standard error of the mean (SEM). In the negative siRNA-transfected 
group, the mean fold change was 1.0 ± 0.1, which remained statistically unchanged 
in the three experimental conditions. However, the cells transfected with siRNA 3 
trended towards a knockdown of ERβ RNA in Figs. 5A and 5B, which was trending 
towards significance (p = 0.42 and 0.27, respectively, compared to between 0.8 and 
0.9 for the other experimental conditions).  
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Figure 5 – Levels of oestrogen receptor β (ERβ) RNA expression in SW1736 cells 
transfected with either a negative control siRNA or one of three siRNAs targeted 
against ESR2, in terms of delta CT values (A) and fold change (B). Data were obtained 
from q-PCR and are mean values (n = 3 for the siRNA 2 and siRNA 3 experimental 
groups; n = 4 for the negative and siRNA 1 groups), with error bars showing standard 
deviation (A) and standard error of the mean (B). 
3.1.1.2 Ret 
The SW1736 cells that had been transfected with a negative control siRNA or one of 
three different anti-ESR2 siRNAs were also assayed for RNA expression of Ret in 
order to see if the level of ERβ RNA expression had any effect on the level of Ret 
RNA expression in this cell line. Fig. 6 below shows the level of Ret RNA expression 
in SW1736 cells transfected with either a negative control siRNA or one of three 
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different siRNAs targeted against the ESR2 gene. Fig. 6A shows the mean delta CT 
values of Ret RNA expression in each experimental group, with error bars 
representing SD. The mean delta CT value for the negative siRNA-transfected group 
was 26.6 ± 0.3, which was statistically unchanged in the groups transfected with any 
anti-ESR2 siRNA. However, the delta CT value of the cells transfected with siRNA1 
trended towards an increase to 27.1 ± 0.4 in the group treated with siRNA 1, which 
was approaching significance (p = 0.09). Fig. 6B shows the mean fold change of Ret 
RNA expression, with error bars representing SEM. The mean fold change in the 
negative siRNA-transfected group was 1.0 ± 0.1, which remained statistically 
unchanged in all experimental groups.  However, the fold change trended towards 
an increase in Ret RNA expression in the siRNA 2-transfected group to 1.3 ± 0.2, 
and trended towards a decrease in Ret RNA expression in the siRNA 1-transfected 
group to 0.7 ± 0.1. Both of these changes were approaching significance (p = 0.30 
and 0.10, respectively). 
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Figure 6 – Levels of Ret RNA expression in SW1736 cells transfected with either a 
negative control siRNA or one of three siRNAs targeted against ESR2, in terms of 
delta CT values (A) and fold change (B). Data were obtained from q-PCR and are mean 
values (n = 3 for the siRNA 2 and siRNA 3 experimental groups; n = 4 for the negative 
and siRNA 1 groups), with error bars showing standard deviation (A) and standard 
error of the mean (B). 
3.1.2 Western blot 
SW1736 cells were transfected with either a negative control siRNA or one of three 
different anti-ESR2 siRNAs in order to see if significant knockdown of ERβ could be 
achieved at the protein level in this cell line. Figs. 7 and 8 below are repeats of the 
same experiment, so contain the same protein samples, but only 20µg of protein was 
loaded into each well in Fig. 7, and this membrane was blocked with milk and 
exposed to X-ray film for 30 minutes, whereas 40µg of protein was loaded into each 
60 
 
well in Fig. 8, and this membrane was blocked with BSA and exposed to X-ray film 
for 1 minute, due to high levels of background staining. ERβ was detected around 
55kDa, while β-actin was detected around 50kDa, and bands were analysed using 
densitometry (see Section 2.9.1). Fig. 7A shows the level of ERβ protein expression 
in SW1736 cells transfected with either a negative control siRNA or one of three 
different siRNAs targeted against the ESR2 gene. The two lanes containing samples 
transfected with the negative siRNA showed a clear band at 55kDa. This band was 
significantly weaker in the lanes containing samples transfected with siRNA 1 
(s4826) and siRNA 2 (s4827), with the bands almost non-existent in the siRNA 1-
transfected group (p < 0.05). The bands trended towards being weaker in the lanes 
containing samples transfected with siRNA 3 (s4828), although this was not 
significant. Fig. 7B shows the level of β-actin protein expression in each 
experimental group. The much darker β-actin bands in these lanes in Fig. 7B 
suggests more protein was loaded in these lanes, whereas the bands in other lanes 
showed a more even protein loading. Fig. 8A also shows the level of ERβ protein 
expression in SW1736 cells transfected with either a negative control siRNA or one 
of three different siRNAs targeted against the ESR2 gene. The band densities 
remained statistically unchanged in all experimental conditions, despite trending 
towards weaker bands in each anti-ESR2 siRNA-transfected group. Fig. 8B shows 
fairly consistent bands of β-actin in each lane, showing even protein loading.  
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Figure 7 – Western blot showing oestrogen receptor β (ERβ) protein expression (A) 
and β-actin protein expression (B) in SW1736 cells transfected with either negative 
control siRNA or one of three siRNAs targeted against ESR2. Amount of protein 
loaded was 20µg, with 30 minute exposure to X-ray film. * = p < 0.05 (Student’s t-test) 
 
 
Figure 8 – Western blot showing oestrogen receptor β (ERβ) protein expression (A) 
and β-actin protein expression (B) in SW1736 cells transfected with either negative 
control siRNA or one of three siRNAs targeted against ESR2. Amount of protein 
loaded was 40µg, with 1 minute exposure to X-ray film. 
3.2 Data for MCF7 cells transfected control or anti-ESR2 siRNA, and 
treated with or without oestrogen  
3.2.1 Quantitative-PCR 
3.2.1.1 ERβ 
MCF7 cells (a human breast carcinoma cell line) were transfected with either a 
negative control siRNA or a combination of two different anti-ESR2 siRNAs (s4826 
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and s4827) in order to see if significant knockdown of ERβ could be achieved at the 
RNA level in this cell line. Furthermore, these transfected cells were then treated 
either with or without 10nM oestradiol (E2) in order to see if the presence of 
oestrogen significantly affected the level of expression of ERβ RNA. Fig. 9 below 
shows the level of ERβ RNA expression in MCF7 cells transfected with either a 
negative control siRNA or a combination of different siRNAs against ESR2 (s4826 
and s4827), and then either treated with or without 10nM oestradiol (referred to as 
negative, negative + E2, siRNA, and siRNA + E2 in the rest of this thesis). Fig. 9A 
shows the mean delta CT values of ERβ RNA expression in each experimental 
group, with error bars representing SD. The mean delta CT value for the negative 
group was 19.8 ± 0.3, which was statistically unchanged in the negative + E2 and 
siRNA + E2 groups. However, the mean CT value was significantly increased to 
20.4±0.3 in the siRNA group (p < 0.05). Fig. 9B shows the mean fold change in ERβ 
RNA expression, with error bars representing SEM. The mean fold change in the 
negative group was 1.0 ± 0.1, which was statistically unchanged in the negative + E2 
and siRNA + E2 groups. Conversely, the mean fold change was significantly 
decreased to 0.6 ± 0.1 in the siRNA group (p < 0.05). 
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Figure 9 – Levels of oestrogen receptor β (ERβ) RNA expression in MCF7 cells 
transfected with either a negative control siRNA or a combination of two siRNAs 
targeted against ESR2; and either treated with 10nM oestradiol or not, in terms of 
delta CT values (A) and fold change (B). Data were obtained from q-PCR and are mean 
values (n = 3 for the negative without oestradiol and negative with oestradiol 
experimental groups; n = 4 for the siRNA without oestradiol and siRNA with oestradiol 
groups), with error bars showing standard deviation (A) and standard error of the 
mean (B). * = p < 0.05 (Student’s t-test) 
3.2.1.2 Ret 
The MCF7 cells from the above experimental conditions were also assayed for RNA 
expression of Ret, in order to see if Ret RNA expression was significantly affected by 
ERβ expression and/or the presence of oestrogen in this cell line. However, the Ret 
RNA expression levels were so low that they could not be detected in the majority of 
samples. Consequently, these data could not be presented. 
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3.2.1.3 Cyclin D1 
The MCF7 cells from the above experimental conditions were also assayed for RNA 
expression of cyclin D1, in order to see if levels of ERβ RNA and/or the presence on 
oestradiol had any significant effect on the levels of cyclin D1 RNA in this cell line. 
Cyclin D1 was investigated because it is a known oestrogen-responsive gene, and is 
critical for progression through the cell cycle [2, 6, 18, 21, 25-27]. Fig. 10 below 
shows the level of cyclin D1 RNA expression in MCF7 in the experimental conditions 
as above: negative, negative + E2, siRNA, and siRNA + E2. Fig. 10A shows the 
mean delta CT values of cyclin D1 RNA expression in each experimental group, with 
error bars representing SD. The mean delta CT value for the negative group was 
11.3 ± 0.5, which was statistically unchanged in all experimental groups. However, 
the mean delta CT values trended towards an increase to 11.9 ± 0.4 and 11.9 ± 0.3 
in the siRNA and siRNA + E2 groups, respectively, which was approaching 
significance (p = 0.12 and 0.09, respectively). Fig. 10B shows the mean fold change 
in cyclin D1 RNA expression, with error bars representing SEM. The mean fold 
change in the negative group was 1.0 ± 0.2, which was statistically unchanged in all 
experimental conditions. However, in the siRNA and siRNA + E2 groups, the mean 
fold change trended towards a decrease to 0.7 ± 0.1 and 0.7 ± 0.1, respectively, 
which was approaching significance (p = 0.14 and 0.11, respectively). 
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Figure 10 – Levels of cyclin D1 RNA expression in MCF7 cells transfected with either a 
negative control siRNA or a combination of two siRNAs targeted against ESR2; and 
either treated with 10nM oestradiol or not, in terms of delta CT values (A) and fold 
change (B). Data were obtained from q-PCR and are mean values (n = 3 for the 
negative without oestradiol and negative with oestradiol experimental groups; n = 4 
for the siRNA without oestradiol and siRNA with oestradiol groups), with error bars 
showing standard deviation (A) and standard error of the mean (B). 
3.2.1.4 IGF-1R 
The MCF7 cells from the above experimental conditions were also assayed for RNA 
expression of IGF-1R (insulin-like growth factor type 1 receptor), in order to see if the 
levels of IGF-1R RNA are significantly affected by levels of ERβ RNA and/or the 
presence of oestradiol in this cell line. IGF-1R was investigated because it is known 
to be an oestrogen-responsive growth factor receptor and is involved in cell growth 
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and proliferation [2, 6, 10, 12, 18, 19, 21]. Fig. 11 below shows the level of insulin-
like growth factor type 1 receptor (IGF-1R) RNA expression in MCF7 cells in the 
experimental conditions as above: negative, negative + E2, siRNA, and siRNA + E2. 
Fig. 11A shows the mean delta CT values of IGF-1R RNA expression in each 
experimental group, with error bars representing SD. In the negative group, the 
mean delta CT value was 11.6 ± 0.6, which was statistically unchanged in each 
experimental condition. However, all three experimental conditions did trend towards 
a decrease in IGF-1R RNA levels, which was trending towards significance             
(p = 0.64, 0.69, and 0.43, for negative+E2, siRNA, and siRNA+E2, respectively). Fig. 
11B shows the mean fold change in IGF-1R RNA expression, with error bars 
representing SEM. The mean fold change in the negative group was 1.1 ± 0.3, which 
was statistically unchanged in all experimental conditions. However, the siRNA + E2 
group trended towards an increase in IGF-1R levels, which trended towards 
significance (p = 0.48). 
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Figure 11 – Levels of insulin-like growth factor type 1 receptor (IGF-1R) RNA 
expression in MCF7 cells transfected with either a negative control siRNA or a 
combination of two siRNAs targeted against ESR2; and either treated with 10nM 
oestradiol or not, in terms of delta CT values (A) and fold change (B). Data were 
obtained from q-PCR and are mean values (n = 3 for the negative without oestradiol 
and negative with oestradiol experimental groups; n = 4 for the siRNA without 
oestradiol and siRNA with oestradiol groups), with error bars showing standard 
deviation (A) and standard error of the mean (B). 
3.2.2 Western blot  
MCF7 cells were transfected with a negative control siRNA or a combination of two 
different anti-ESR2 siRNAs (s4826 and s4827), and then treated either with or 
without 10nM oestradiol, in order to see if significant knockdown of ERβ could be 
achieved at the protein level in this cell line, and whether the presence of oestrogen 
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has any effect on the amount of ERβ protein expressed. Fig. 12 below shows 50µg 
protein in each well. However, there was not enough protein harvested from the cells 
transfected with negative control siRNA and treated without oestradiol, so it could not 
be loaded into the gel. The membrane was blocked in BSA (see Figure 12C and 
Section 2.9) and exposed to X-ray film for 1 minute, as background staining was high 
with prolonged exposure. ERβ was detected around 75kDa, as there was no 
consistent band detected closer to 55kDa, even at a longer exposure, while β-actin 
was still detected around 50kDa, and bands were analysed using densitometry (see 
Fig. 12C and Section 2.9.1). Fig. 12A shows the level of ERβ protein expression in 
MCF7 cells transfected with either negative control siRNA or a combination of two 
different siRNAs targeted against ERβ (s4826 and s4827), and either treated with or 
without 10nM oestradiol. Densitometry analysis (Fig. 12C) showed that there was no 
significant difference in ERβ expression in the three experimental groups, although 
the two groups transfected with anti-ESR2 siRNA trended towards weaker bands, 
which were approaching significance (p = 0.20 and 0.12 for the siRNA and siRNA + 
E2 groups, respectively). However, there was no statistical difference between ERβ 
expression in the samples transfected with siRNA and then treated with or without 
oestradiol.  Fig. 12B shows fairly consistent β-actin bands, indicating even protein 
loading. 
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Figure 12 – Western blot showing oestrogen receptor β (ERβ) protein expression (A) 
and β-actin protein expression (B) in MCF7 cells transfected with either a negative 
control siRNA or a combination of two siRNAs targeted against ESR2; and either 
treated with or without 10nM oestradiol. C shows the densitometry values of the ERβ 
and β-actin bands in each of the lanes, numbered 1-6 from left to right. 
4.0 Discussion  
4.1 Success of ERβ knockdown 
In order to establish potential effects of inactive ERβ mutations on tumourigenesis, 
we needed to experimentally replicate the loss of functional ERβ. This was done by 
transfecting SW1736 (a human thyroid carcinoma cell line) and MCF7 (a human 
breast carcinoma cell line) cells with anti-ESR2 siRNA and examining levels of ERβ 
RNA and protein expression via q-PCR and Western blotting, respectively.  
While the data in Figs. 5 and 8 showed a trend towards decreased ERβ expression 
with siRNA transfection at the RNA and protein level, respectively, in SW1736 cells, 
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only Fig. 7 showed a significant reduction in ERβ protein expression in these cells 
when transfected with siRNA 1 (s4826) or siRNA 2 (4827) (p < 0.05). The fact that a 
significant reduction in ERβ protein expression was only seen in Fig. 7 and not Fig. 
8, even though Fig. 8 was loaded with double the protein concentration of all 
samples from Fig. 7, was unexpected. However, there was a substantial time period 
between running the two blots, with the samples being stored at -20oC, so it is 
possible that there was some protein degradation during that time, especially during 
the thawing process. 
Conversely, Fig. 12 only shows an insignificant trend towards decreased ERβ protein 
expression in the MCF7 cell line. Fig. 9 shows that there was significant knockdown 
of ERβ RNA expression in this cell line when transfected with a combination of two 
anti-ESR2 siRNAs (s4826 and s4827) and then treated without oestrogen.  
These data show that there was some knockdown of ERβ in both cell lines at the 
RNA and protein level. However, this was only significant in two experiments. 
Consequently, the knockdown conditions needs to be optimised to consistently 
achieve knockdown at both the RNA and protein level in both cell lines, in order for 
subsequent experiments to be validated. However, time constraints prevented this 
from occurring. 
4.2 Effect of ERβ knockdown on the expression of Ret, cyclin D1 and 
IGF-1R 
The effect of reduced ERβ expression on the RNA levels of the proto-oncogene Ret, 
the cell-cycle regulator cyclin D1, and the growth factor receptor IGF-1R, was then 
investigated via quantitative polymerase chain reaction (q-PCR). 
71 
 
Fig. 6 shows that there was no consistent, significant change in Ret RNA expression 
when ERβ levels were reduced (albeit insignificantly) in the SW1736 cell line. 
Furthermore, the lack of data for Ret RNA expression in the MCF7 samples shows 
that Ret expression was very low in all of these samples, regardless of the amount of 
ERβ RNA expression (Fig. 9). 
Furthermore, Fig. 11 does not show a significant change in IGF-1R RNA expression 
in MCF7 cells, despite a significant reduction in ERβ RNA (Fig. 9). 
Fig. 10 shows a trend towards a decrease in expression of cyclin D1 RNA when ERβ 
RNA levels were significantly reduced in MCF7 cells (Fig. 9). This trend was 
approaching significance (p = 0.13 on average). 
Together, these data show that significant ERβ RNA knockdown did not have any 
significant effect on the expression of Ret, cyclin D1, or IGF-1R, at the RNA level in 
MCF7 cells, or the expression of Ret RNA in SW1736 cells. This suggests that the 
expression of these genes are unaffected by the level of ERβ expression in this cell 
line, although the trend towards a decrease in cyclin D1 in MCF7 cells was 
approaching significance, suggesting that cyclin D1 expression may depend on ERβ 
expression. Further repeats would be needed to confirm this, but time constraints 
prevented this from occurring. 
It has been shown previously that oestrogen induces Ret expression and drives cell 
proliferation [10]. However, these data suggest that a reduction in functional ERβ 
expression may not be solely responsible for alterations in Ret expression in the 
initiation and/or progression of MTC, as there is no consistent trend between ERβ 
and Ret expression observed. Furthermore, from this data, it seems unlikely that 
MTC develops through a pro-proliferative change in cyclin D1 expression with 
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reduced functional ERβ expression. Overexpression of cyclin D1 is often observed in 
cancers, as this drives transition through the cell cycle [6, 21, 25-27], and in order to 
support the idea that ERβ keeps cell proliferation in check, we should see an 
increase in cyclin D1 expression when ERβ is knocked down [2, 18], instead of the 
decrease observed in this data. These data show that only IGF-1R trended towards 
an increased RNA expression when ERβ was knocked down in the MCF7 cell line. 
This was to be expected, as it has been found previously that IGF-1R expression is 
associated with increased cell proliferation and tumour progression [12], and that 
IGF-1R is involved in ligand-independent ERα signalling [19], which will go 
unregulated due to ERβ knockdown [2, 6, 10, 18, 21]. Consequently, it may be that 
this is the pathway in which MTC is initiated or progresses when ERβ is mutated. 
However, as this change was not significant, this cannot be confirmed, so further 
repeats are needed, as time constraints prevented this from happening. 
4.3 Effect of oestrogen on ERβ, Ret, cyclin D1 and IGF-1R expression 
Fig. 9 suggests that oestradiol reduces ERβ RNA expression in negative siRNA-
transfected MCF7 cells; while it increases ERβ RNA expression in anti-ESR2 siRNA-
transfected cells, although this was insignificant. Fig. 12 does not show any effect of 
oestradiol on the expression of ERβ protein in MCF7 cells transfected with siRNA. 
Neither of these figures shows a significant effect of oestrogen on ERβ expression at 
the RNA or protein level, suggesting that oestrogen does not regulate ERβ 
expression. Alternatively, it may be that because of the knockdown level of ERβ in 
both cell lines, there is less ERβ to be upregulated by the presence of oestradiol. 
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As there were negligible amounts of Ret RNA expression across MCF7 cells from all 
experimental conditions, no data could be presented. This suggests that oestrogen 
has no effect on Ret RNA expression. 
Fig. 10 shows that oestradiol does not affect the level of expression of cyclin D1 
RNA in MCF7 cells, as there is little difference between the delta CT values and fold 
change levels between the respective groups.  
Fig. 11 shows that oestradiol does not have an effect on IGF-1R RNA expression in 
MCF7 cells with normal ERβ RNA expression, but that oestradiol seems to have a 
greater effect on increasing IGF-1R RNA expression in MCF7 cells with a 
significantly reduced ERβ RNA expression (Fig. 11).  
Together, these data suggest that oestrogen has no significant effect on the amount 
of ERβ, Ret, cyclin D1, or IGF-1R RNA expression. However, it has been found 
previously that oestrogen acting through ERα has a pro-proliferative role, whereas it 
has an anti-proliferative role when acting through ERβ, through reducing the 
transcriptional activity of ERα [6, 18, 20]. This has been shown previously, as 
activation of ERβ signalling through the use of its agonist diarylpropionitrile (DPN) 
and adenovirus-mediated transfection resulted in reduced cell proliferation and 
migration, due to reduced expression of cyclin D1 [2] and the anti-apoptotic protein 
Bcl-2 [6, 21], and increased apoptosis, due to increased expression of the pro-
apoptotic protein caspase-3 [2]. Consequently, when ERβ is knocked down, there 
should be increased expression of the various genes activated by ERα signalling 
which are responsible for cell proliferation, growth and migration, such as Bcl-2, 
which has been shown previously [6, 21]. However, as there were trends towards 
decreased RNA expression of these oestrogen-responsive genes, it may be that 
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there was some RNA degradation and/or degradation of the fluorescence signal from 
the Taqman assays occurring, as technological problems meant that the plates spent 
longer in the light than normal (Taqman assays are slightly light sensitive), and had 
to be stored at -20oC, so there may have been some RNA degradation during the 
thawing process. Consequently, these experiments should be repeated, but time 
constraints prevented this from occurring. 
4.4 Areas for future work 
While there were replicates in each experimental condition in each experiment 
carried out (n = 4 for RNA transfection; n = 2 for protein transfection) and duplicates 
of each sample were assayed (see Section 2.0), and the mean of these was taken, 
data were only collected once from each experiment, as time and resource 
constraints only allowed one repeat to be carried out. In order to improve the validity 
of these results, data needs to be collected from further repeats of each experiment. 
Furthermore, the effect of 10nM oestradiol on ERβ, Ret, cyclin D1 and IGF-1R RNA 
expression and ERβ protein expression in negative control or anti-ESR2 siRNA-
transfected SW1736 cells should also be investigated using q-PCR and Western 
blotting, respectively, as time and resource constraints prevented this from occurring. 
It would also be beneficial to investigate the effect of anti-ESR2 siRNA and 
oestrogen on the level of Ret, cyclin D1 and IGF-1R protein expression by Western 
blotting in both cell lines, as time constraints did not allow this to happen. It would 
also be worth investigating the consequent expression of other genes known to be 
oestrogen-responsive and/or be involved in regulation of the cell cycle or migration, 
such as the growth factor receptors VEGFR and EGFR [3-5, 12, 14], the 
transcription factor NFκB [28], the anti-apoptotic protein Bcl-2 [6, 21], the proto-
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oncogene c-myc [2], or the cytoskeletal-linker proteins ezrin and moesin [29, 30], in 
order to understand this pathway better, as time and resource constraints did not 
facilitate this. 
To further investigate the role of ERβ and oestrogen in tumourigenesis, the level of 
cell proliferation and migration in both cell lines with either wild-type or knockdown 
levels of ERβ, and treated with or without oestrogen, should be examined, as time 
constraints prevented this from happening. This could be done by MTS or MTT 
assays, or BrdU assays to see if reduced ERβ expression affects cell proliferation 
and migration, and whether the presence of oestrogen has any impact. If ERβ 
knockdown significantly increases the proliferation and migration of these cell lines, it 
would show that mutated, dysfunctional and/or reduced levels of ERβ can be 
responsible for the initiation and progression of MTC. 
In order to confirm that ERβ is essential for cell cycle regulation and that a loss of 
functional ERβ can be responsible for developing MTC, these cell lines should be 
transfected with wild-type ERβ to examine the effects of over-expressing ERβ. 
These cells should have significantly reduced proliferation and migration compared 
to control in order to support this hypothesis. Furthermore, transfection with mutated 
forms of ERβ should result in increased rates of cell proliferation and migration.  
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